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phase seems, therefore, most suitable to eliminate unwanted side effects. 
Studies of structure-activity relationship both for the desired and for 
the unwanted effects provide means to find out whether particular struc-
tural changes lead to a separation of these effects. Such a separation 
is principally only possible if the types of receptors involved, in main 
and side effect, are different. In this case high activities will in 
general contribute to selectivity in action, since high activity usually 
will be based on a high degree of complementarity between drug and re-
ceptor. A high degree of complementarity towards different types of re-
ceptors is unlikely. 
As a matter of fact in the discussion of structure-activity rela-
tionship, the concept of a drug-receptor interaction is at the background. 
The part-processes involved in the drug-receptor interaction as far as 
the role of the various groups in the bioactive molecule in the inter-
action is concerned are not taken into account. 
While structure-activity relationship studies mainly are an approach 
on the molecular level, structure-action relationship studies are an ap-
proach primarily on the submolecular level. In this latter approach the 
interaction of the drug molecule with its active site is analysed in 
terms of the contributions of the various groups of the drug molecule. 
Moreover, the spatial demands of the receptor with respect to the diffe-
rent groups in the pharmacon molecule are taken into account (5). As far 
as the spatial relationship is concerned, rigid molecules with an optimal 
fit to one type of receptors will have a higher chance of selectivity in 
action than flexible molecules, that can fulfil the sterical requirements 
of more than one type of receptors. Fig. 1 illustrates how in diphen-
hydramine a highly flexible molecule with both an anticholinergic and an 
antihistaminic action, introduction of rigidity by suitable ring substi-
tutions results in selectivity to the anticholinergic or selectivity to 
the antihistaminic activity. Introduction of a t-butyl group in the ortho 
position results in a high anticholinergic and a low antihistaminic ac-
tivity, while introduction of a methyl group in the para position results 
in a high antihistaminic and a low anticholinergic activity. Here we are 
really approaching the boarderline between the structure-activity rela-
tionship and structure-action relationship. 
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Fig. ]. Increase of specificity in action of diphenhydramine derivatives 
as a result of a decrease in degree of conformational freedom. 
(After Harms and Nauta, 6) 
One may, for instance, expect that the ratio of the activities of 
optical isomers will be large for highly potent agents, where an opti­
mal fit of the more active isomer with regard to their sites of action 
may be assumed, while this ratio will be small for less potent agents. 
This is examplified by the tertiary butyl derivatives and the para 
methyl derivatives mentioned in Fig. 1. Both derivatives have a centre 
of asymmetry. For the tertiary butyl derivative, the ratio for the op­
tical isomers is high for the anticholinergic and low for the antihis-
taminic activity while for the para methyl derivatives this ratio is 
high for the antihistaminic activity and low for the anticholinergic 
activity (Fig. 2). These relationships clearly deal not only with the 
activity but also and especially with the selectivity in action of bio-
active rgents. 
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Fig. 2. Increase of the aativity ratio in optical isomers of diphen-
hydramine derivatives as a result of an increase of the potency. 
(After Bekker et al., 7) 
Selectivity in action (8) can be traced back to a complementarity of 
electron density distribution in the drug molecules and the receptor 
site on the macromolecule, which is inherent to the specificity in 
interaction (9). 
The objective of the investigations described in this thesis is to 
contribute to the insight in the factors determining specificity in 
drug-receptor interaction. Albumin has been used as a model system as 
to simulate such interactions. The bovine serum albumin used is a pro-
perly defined protein (MW 66,000) (10, 11) available in high purity 
(11). It displays specific (12, 13) as well as non-specific (14, 15) 
binding of drugs. 
Section I deals with the specificity in hydrophobic interaction as 
investigated by binding of a series of fatty acids to albumin. In the 
literature many examples are reported of a correlation between lipophi-
licity of drugs and their activity. The same holds true for the affinity 
of drugs to proteins. Since lipophilicity, if expressed in terms of par-
tition coefficients (3), is practically independent of the spatial ar-
rangement of the groups in the molecules it seems doubtful whether it 
can lead to specificity in action. However, the hydrophobic binding 
areas present on or in the protein may be assumed to have a limited 
size, taken into account the size of the constituting hydrophobic amino 
acid side chains. This might well imply that nevertheless a more detailed 
analysis might show an involvement of hydrophobicity in the specificity 
of action. The possibility of hydrophobic contributions to selectivity in 
action has been approached by measuring binding constants of fatty acids. 
In the case of extensive, quasi continuous, hydrophobic binding areas, a 
monotonous increase of the binding constant may be expected with each 
addition of a methylene group to the fatty acid. In the case, however, 
of more restricted hydrophobic areas such as postulated before, one ex-
pects discontinuities in this increase there where the fatty acid chain 
leaves a hydrophobic area and must bridge a more polar area to reach a 
possible neighbouring hydrophobic area again. 
Section II presents a study of the selectivity in binding of ace-
trizoate (a renal contrast medium) to different binding sites of albumin 
on basis of nuclear magnetic resonance (nmr). In the first paper of this 
section attention is focussed upon the mobility of the methyl group of 
acetrizoate in relation to the aromatic ring. The anisotropic rotation 
of the methyl group causes a clear non-exponential relaxation of the 
magnetization which disappears when acetrizoate binds to albumin. Another 
feature of the nmr spectrum, dealt with in the second paper of this sec-
tion, is the dependence of linewidth on exchange rates namely the rate 
of exchange of drug molecules between bound and unbound state (16). On 
this basis the selectivity acetrizoate displays for the different bin-
ding sites of albumin has been explored in relation to the rate constants 
involved in the binding. 
Whether drug-protein binding interferes with, for example, active 
renal excretion, greatly depends on the rate constants involved in the 
binding. This matter is discussed in the third paper of this section. 
NMR offers the possibility for estimating the mobilities of the dif-
ferent groups of the pharmacon molecule when bound to the receptor (17). 
This opens perspectives for estimating the participation of the different 
groups in the binding process. Such investigations are still in its in-
6 
fancy. Up to now efforts to gain information on group participation in 
drug-receptor interaction have been mainly restricted to the study of 
the difference in activity of stereoisomers. 
Section III deals with an analysis of stereoselectivity as a basis 
for the mechanism of specific interactions (5). As elucidated before, 
for highly active compounds with a centre of asymmetry, for one isomer 
a high degree of complementarity and thus a close fit between that mo-
lecule and its site of action must be assumed. This then is impossible 
for the other isomer, such that a large activity ratio is to be expected. 
For poorly active compounds with a centre of asymmetry a poor fit may be 
assumed also for the more active isomer, such that in that case the ac-
tivity ratio of both isomers will tend to become 1. This should hold true 
in general for interactions of bioactive molecules such as drugs and 
enzyme substrates with their sites of action. A survey of relevant data 
from the literature, presented in the first paper of this section, 
clearly supports this concept. In the second paper the concept is ra-
tionalized on basis of a model dealing with drug receptor interaction 
on a submolecular level. 
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SECTION I 
SPECIFICITY IN HYDROPHOBIC INTERACTION 
Thin-layer chromatographic separation of free fatt/ acids 
Analysis and purification of radioactively labelled fatty acids 
J. F. RODRIGUES DE MIRANDA and Τ D EIKELBOOM 
Department of РИагтасоІоц), Unnersit) of hijmegen, Nijmegen (The Netherlands) 
(First received February 19th, 1975, revised manuscript received June 5th, 1975) 
In a research project oflhis laboratory, binding of fatty acids to bovine serum 
albumin is used as a model system for studying drug-bmmacromolecule interaction. 
Determination of the concentration ol Iree and bound fatty acids in equilibrium-
dialysis experiments can be accomplished by using 14C-labelled fatty acids, although 
in the dialysis experiments, the '•'C-labelled fatty acids are diluted many times with the 
l2C-isotope analogues, the binding of the labelled compounds is monitored For this 
reason, the labelled latty acids must be essentially free from contaminating radioactive 
compounds. 
To check their purity, chromatographv is chosen, as this technique can be ap­
plied for analysis as well as punlication ol the compounds In order to limit the num­
ber of operations with radmacmc material bclore ami alter the purification, there is 
a preference for analysis ol the Iree latt> acids (f Ι Л) rather than their derivatives. 
Moreover, as the relative change in physico-chemical piopcmes (lipophilicity) is larger 
in a series of Fí-Λ than in their derivatives or salts, chromatographic separation of 
the FFA is preferable. Paper' and thin-layer-' chromatographic (11С) methods de­
scribed for separating I FA as ammonium salts report /f, values lor the C 7 to C, acids 
that are too close to allow easy purification 
The difficulty in obtaining reproducible R, values in PLC with methyl acetate-
2.5 %aq. ammonia (95:5, ν ν) as developing solvent was another I actor that persuaded 
us to seek an alternative chromatographic method 
The excellent gas chromatographic3 , and eleclrophoretic'' separation of Ff A 
cannot easily be adapted to the preparative separation of radioactive I FA. This con­
trasts with TLC, which, in addition, is relatively inexpensive and requires only com­
pact equipment7. 
As silanised silica gel has become commercially available for TLC, it is now 
possible to separate FFA by rcversed-phase chromatography7 H Thus, it appeared to 
us to be worthwhile to look for a simple solvent system for use with this lipophilic 
adsorbent. As will be shown, we have succeeded in obtaining good separations for the 
C 2 to С, FFA with a methanol water system, and have devised a system satisfactory 
for the purification of '''C-labclled C5, Cfc and C 7 FFA. 
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MATERIALS 
The propionic (C3), butyric (C4) iind hexanoic (C6) acids were obtained from 
Baker (Dc\cnter, The Netherlandb) The pentanoic (C5) acid was from Koch-Light 
(Colnbrook. Great Britam) and the heptanoic (C7) acid was from Fluka (Buchs, 
Switzerland) The purity of these acids was checked by gas chromatography at 200' 
on a column of Porapak Q and was found to be better than 9 9 % by the internal-
standard procedure 
The [l-'4C]-labelled acids, as sodium salts, were obtained from The Radio­
chemical Centre (Amersham Great Britain) and had specific activities ranging from 
10-20 mCi/mmole These labelled salts were stored at —20 as stock solutions in 
methanol containing SO/iO/inl 
The TLC plates (20 Ν 20 cm) were prepared with Desaga equipment (Desaga, 
Heidelberg, G F R ) according to thespccihcations for the silica gel (H F 254, silanised, 
L Merck, Darmstadt, G F R ) 
The scintillation liquid, Insta-gcl, was from Packard (Brussels, Belgium) and 
counting was performed on a Packard Tricarb liquid scintillation spectrometer The 
direct-contact X-ray film was Kodak RP 54 
All other materials used were from h Merck 
METHODS AND RESULTS 
The liquid non-labelled FF A were diluted five times with methanol before 
being applied to the plate I or the analytical separation, 10μΐ ol the stock solution 
of the radioactive acid (C„. sodium salt) was placed in the tip of a conical tube, and 
1 μΙ of undiluted FF A mixture (C,,., C„ CI1 + , — 1 I I) was added This mixed sam­
ple was suflicient for about five spots of diameter 3 mm All processes involving FF A 
were carried out at 4 
For the preparative separation of radioactive I FA, 250 μΐ of the radioactive 
stock solution was placed in the tip ol a conical tube and the solvent was evaporated 
at 60 by aspirating olf the vapour The tip was then rinsed with 3μΙ of 1 N hydro­
chloric acid in methanol, and the solution was applied as a "zone" of 4 cm in length 
The initial spots were placed about 2 cm from the edge of the plate, and the solvent 
front was allowed to move 10 cm above the spots All solutions were applied to the 
plate at 4 , and development7 was carried out at the same temperature 
Detection of the non-radioactive FFA was by spraying with a saturated solu­
tion of methyl red m 0 2",) methanolic sodium hydroxide Detection of the radioactive 
F-FA was by autoradiography or by zone analysis With autoradiographic detection, 
the plates were first sprayed with the indicator solution, carefully dried and then 
sprayed with a solution of a fluid adhesive (Lero) in chloroform (this increased the 
resistance of the adsorbent to mechanical damage) Next, an X-ray film was placed 
in direct contact with the adsorbent, the contact time being 24 h for 0 0 5 μ Ο per 
spot The zone analysis was performed by scraping the adsorbent from the wet plate 
in 3-iTim zones at 4 (see ref 9) With an analytical separation, the adsorbent of each 
zone was transferred to a counting phial containing 4 ml of water and 10 ml of Insta-
gel, and the radioactivity m each phial was counted For preparative separation, the 
U 
adsorbent from each zone was transferred to a conical centrifuge tube containing 1 
ml of methanol, and the mixture was stirred 
To determine the position of the mam peak, l-i/l aliquots of the supernatant 
solution in each tube were transferred to a counting phial containing 10 ml of Insta-
gel, and the radioactivity in each phial was counted The fractions containing the 
peak concentration of the acid were centrifuged at 1000 g. and the supernatant solu­
tion containing the purified acid was removed with a pasteur pipette To check that 
the lower FFA had not volatilised during the processes preceding autoradiography, 
recovery experiments with [l-,4C]propionic acid were carried out, recovery of radio­
activity was 97 ±2% 
Development of a suitable solvent system 
The solvent system dioxan-water-formic acid (60 35 5), although having a 
high resolving power for the higher FFA8, is less suitable for separation ol the lower 
FFA, this is mainly due to interference by this solvent system with the detection 
method used 
This disadvantage does not occur with the solvent system methanol water, 
which gives excellent separation of the С} to C9 FFA on silamsed silica gel (see Fig 
la) For optimal resolution, the mcthanol-water ratio depends on the length of the 
carbon chain of the acid being separated The dependence of the RF value on the 
methanol-water ratio is shown in Fig 2 for the eight FFA investigated, from the 
curves in Fig. 2, an optimal ratio can be selected for a given mixture of FFA 
ft I 
ft 
JL H 
1 2 3 t 5 6 7 6 9 
Fig 1 Chromatogram of Ff-A on silamsed silica gel development time, 1 h at 4°, spray reagent, 
saturated methyl red solution in 0 2°ó methanolic sodium hydroxide (a) Non-radioactive FFA, 
solvent methanol-water (35 65) I — propionic acid, 2 butyric acid, 3 = pentanoic aud, 4 = 
hexanoic acid, 5 = heptanoic acid, 6 — octanoic acid, 7 - mixture of propionic and butyric acids, 
8 mixture of butyric, pentanoic and hexanoic acids 9 = mixture of hexanoic, heptanoic and octa-
noic acids (b) Autoradiogram of l'lC-ldbelled fatt> acids, solvent methanol-water (40 60) 1 
propionic acid, 2 mixture of butyric, penlanoic and hexanoic acids to which pure ['"Clbulync 
acid is added 3 — mixture of butyric, pentanoic and hexanoic acids to which pure [14C]pentanoic 
acid is added, 4 - heptanoic acid The hatching indicates the area m which a red colour is visible 
after spraying The blackness corresponds to lhat on the original autoradiogram and indicates the 
position of radioactive material For further details, sec text 
12 
% methanol 
Fig 2 Dependence of the Äf values of I-FA on the methanol-water ratio The curves permit selection 
of an optimal resolving ratio for a given mixture of FFA 
7 6 9 7 β я 
Fig 3 Autoradiograms of 14C-labelled FFA (a) 1,3 - mixtures of propionic, butyric and pentanoic 
acids, 2 — the same, but with the labelled butyric acid being analyzed added to the mixture Solvent 
methanol water (20 80) (b) 4,6 — mixtures of pentanoic, hcxanoic and heptanoic acids, 5 = the 
same, but with the labelled hexanoic acid being analyzed added to the mixture Solvent methanol-
water (50 50) (c) 7, 9 — mixtures of hcxanoic, heptanoic and octanoic acids, 8 — the same, but with 
the labelled heptanoic acid being analyzed added to the mixture Solvent methanol-water (50 50) 
(d) 7, 9 — the same as in (c), 8 - the same, but with the purified ["CJheptanoic acid added to the 
mixture For further details, see legend to Fig 1 
13 
Analysis of label-led free fatly acids 
The radioactive F FA were applied to the plate in the ua> described for the 
analytical separation: spots of non-radioacti\e mixtures were applied on either side 
of the radioactive spots to serve as reference spots. The detection of the labelled FFA 
was by autoradiography (sec I ig. lb), and depending on the results, one of the follow-
ing procedures is carried out. 
(a) If the autoradiogram indicates an impurity content much less than 1 %, as 
shown in Fig. 3a, there is no need for further chromatography. The result is confirmed 
by dilution analysis as the /7-bromophcnacyl ester. 
(b) If the autoradiogram indicates an impurity content of about 1 "ó (as shown 
in Fig. 3b for hexanoic acid), the FI A has now to be analyzed quantitatively by zone 
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Fig. 4 Zone anal>sis and preparative scpai.Uion of "Olabcllcd FF-A on silamsed silica gel. The 
ordinale gives ι lie pcrcenlagc ol i.idioactivily recovered per mm of scraped zone, the abscissa gives 
the R, value of the /one. (a) Zone analysis of" [l4C]licxanoic acid, solvent, mcllianol-ualcr (SO 50) 
The calculated purity is 99 0 2", (b) Preparative scpaialion of ll4C]hcplanoic acid, solvent. 
methanol water (50 50) Fractions II and 12, containing most of the pure heptanoic acid, were stoied 
for furlhcr use. 
14 
elution A fresh chromatogram is made by applying the F FA to the piale in the way 
described for the analytical separation, and detection is by the analytical zone-
analysis method (see Fig 4a) The zone analysis indicates, for hexanoic acid, a total 
amount of contaminating radioactivity of 1 ± 0 200 , which is within limits considered 
as acceptable 
(c) If the autoradiogram indicates an impurity content greater than 1 % (as for 
heptanoic acid in Fig 3c), then, if the impurity has been clearly diagnosed, this FFA 
is directly purified according to the procedure described below 
Purification of labelled FFA 
The radioactive FFA is applied to the plate as described for preparative 
separation, and detection is carried out as for preparative zone analysis, this is demon-
strated for heptanoic acid in Fig 4b The fractions 11 and 12, containing pure 
heptanoic acid, are stored at —20 , the purity of these fractions is confirmed by auto-
radiography (see Fig 3d) 
DISCUSSION 
The methanol-water solvent system in proportions ranging from 10 90 for C2 
to C4 FFA up to 60 40 for C7 to C9 FFA gives excellent and reproducible resolution 
of the individual FFA on silanised silica gel The "comets" of the FFA spots, which 
can impede interpretation of the purity of the labelled FFA (see Fig lb), can be 
avoided by applying mixed spots When mixed spots are applied, the labelled Cn 
FFA is forced to distribute itself between the €„_,, C„ and Cn + 1 FFA spots, this re-
duces "comet" formation dramatically (compare Figs lb and 3a) 
The analytical TLC procedure described has been applied successfully to 14C-
labelled C3 to C, FFA It is noteworthy that, in general, the С
л
 FFA appears not to 
be contaminated with C„
 + i or C,,-! FFA, but with some Cn + 2 and C„_2 FFA 
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THE EXTENT OF HYDROPHOBIC BINDING AREA 
studied by fatty acid binding to albumin 
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INTRODUCTION 
Studies on structure-activity relationships show that hydrophobicity 
not only plays an important role in the drug distribution, but also 
in the interaction of the drug with its site of action, the receptor 
(1). The hydrophobic interaction may contribute substantially to the 
stability of the drug-receptor complex and the high pA -values, 
ranging up to 10 log units as observed, for instance, for anticholiner-
gics and antihistaminics, seem to be a consequence of an effective 
hydrophobic interaction (2, 3). The effectiveness of such an inter-
action has probably an upper limit of about 800-1000 cal per CH- group 
in the case of an alkyl chain. This appears from studies of the free 
energy change for the transfer of amphiphilic compounds like alcohols 
and fatty acids from an aqueous to a lipophilic phase (4). 
From the positive correlation between the lipophilicity of a drug 
and its biological activity, often reported (5, 6), one can, however, 
not conclude, that the hydrophobic binding area on the receptor makes 
no spatial demands to the apolar part of the drug molecule. Different 
studies have been devoted to a systematic exploration of the steric 
and spatial structure of the hydrophobic binding regions on proteins 
(7, 8, 9, 10) and in general, lengthening of the aliphatic side chain 
of a drug molecule does not imply simply an increase in affinity (8, 9). 
In those cases the essential part of the receptor is built up by pro-
teins this finding is not unexpected given the fact of the relatively 
short side chains of the lipophilic amino acids and the small chance 
that three or more of these side chains can form hydrophobic binding 
areas at the surface of the protein in aqueous solution. 
In the studies of Belleau et al. (8) on the binding of alkyl tri-
methylammonium ions to acetylcholinesterase and in those of Marlow 
et al. (9) on the binding of alkyl trimethylammonium ions to "antibody 
binding acetylcholine", the effectiveness of the hydrophobic inter-
action, expressed as the free energy change per methylene group, seems 
to be rather low. It has been our aim to explore the hydrophobic 
binding area in the case of a more effective hydrophobic interaction. 
As will be shown, the first specific binding site on albumin for fatty 
acids meets this requirement. Therefore the extent of the hydrophobic 
binding area on albumin has been measured in terms of alkyl chain 
18 
length by determining the relation between the free energy change of 
binding and the chain length. 
MATERIALS AND METHODS 
The propionic (C,), butyric (C,), caproic (C,) and caprylic (C„) acids 
were obtained from Baker, Deventer, the Netherlands, the valeric (C.) 
acid from Koch-Light Laboratories, Colnbrook, Bucks, England, and the 
heptanoic (C.) acid from Fluka AG, Buchs, S.G., Switzerland. The 
purity of the fatty acids was checked gaschromatographically on a 
porapaque-Q-column with an oven temperature of 200 С and found to be 
over 99% using the internal standard procedure. 
The radioactive compounds were all from the Radiochemical Centre, 
1A 
Amersham, England. The labelled fatty acids-1-C -sodium salts have a 
specific activity ranging from 10-20 mCi/mmole. They were stored at 
-20 С as stock solutions containing 10 yCi/ml and an excess of NaOH. 
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Na was supplied as saline containing 3 uCi/2.5 ml. The radiochemical 
14 
and chemical purity of the fatty acids-1-C were checked by thin-
layer chromatography (11). Crystalline bovine serum albumin (BSA) was 
purchased from Povite, Amsterdam, the Netherlands (batch 462, 517 and 
625) and from Nutritional Biochemicals Corporation, NBC, Cleveland, 
Ohio, USA (batch 3404). The concentration of the albumin solution was 
1% 
measured spectrophotometrically at 279 nm on a Zeiss PMQ-II (E-J,, -
6.67). The pH of the solutions was measured on a Radiometer 26 pH-
meter. The scintillation liquid, Instagel, was from Packard, Brussels, 
Belgium. The samples were counted with standard deviations of 0.2% or 
less in a Packard Tricarb liquid scintillation spectrometer, model 
3380. The cellulose acetate membranes were from AKU, Arnhem, the 
Netherlands. Before use they were thoroughly rinsed in démineraiized 
24 
water. Na was counted on a Philips γ-scintillation counter PW 4003. 
All other materials were from E. Merck AG, Darmstadt, Germany. 
The binding of the fatty acids to the protein was determined in 
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equilibrium dialysis experiments. The dialysis apparatus was made after 
a design of A.S.V. Burgen (12). It consists of six pairs of shallow 
teflon cells of 3.5 ml volume each separated by a cellulose acetate 
membrane and clamped together (Fig. 1). 
Fig. 1. Dialysis apparatus made after a design-of Burgen (12); it con­
sists of six pairs of shallow teflon cells, of 3.5 ml volume 
each, separated by a cellulose membrane and clamped together. 
The albumin solution is brought at one side of the membrane, the fatty 
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acid solution, containing tracer amounts of 1-C -labelled fatty acids, 
at the other side. If not otherwise stated, all solutions were made in 
a phosphate buffer pH 6.9, ionic strength 0.1, containing 0.02% NaN as 
a bacteriostatic. The apparatus rotates at the rate of 1 rpm in a 
thermostatic water-bath. Depending on the chain length of the fatty 
acid, equilibrium was reached within 6-8 hours at 30 С and within 
16-20 hours at 40C. 
DETERMINATION OF FATTY ACID CONCENTRATION AT EQUILIBRIUM 
After equilibrium was reached 500 μΐ aliquots from the solutions on 
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both sides of the membrane were taken. To each aliquot 11 ml of an 
Instagel-water mixture (10 : 1) were added, and the radioactivity was 
counted and compared with a reference with a known fatty acid content. 
The counting efficiency is 88.3% (SD 0.1) and independent of the BSA and 
fatty acid concentrations in the range applied. By applying the appro­
priate correction for the Donnan-ratio (13, 14) and the plasma water 
(15), the concentration of F.A. bound to albumin can be calculated by 
subtracting the free concentration (one side of the membrane) from 
the total concentration (other side of the membrane). 
DETERMINATION OF THE PROTEIN CONCENTRATION 
Especially at higher albumin concentrations, i.e. 6.6%, an osmotic 
dilution of the albumin solution occurs during dialysis. For this 
reason albumin concentrations were determined after equilibrium has 
been reached. The Donnan ratio's occurring at the different circum-
24 
stances were determined by the distribution of Na across the mem­
brane. 
THEORETICAL BACKGROUND 
MULTIPLE BINDING 
The association between a small molecule S and a binding site Ρ on a 
protein can be described by the following reaction equation: 
Ρ • s ^ p s κ -
 Ί
Μ _ M"1 (1) 
If the protein contains η independent and identical sites it holds 
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true that: 
and 
[PS| - Í P0 (2) 
[P] = (n - i) P0 (3) 
in which r is the average number of substrate molecules bound to the 
protein molecule and Pn is the total proteir 
tution of eqs. 2 and 3 in eq. 1 results in: 
in concentration. Substi 
К [S] (4) 
[f] - Kí - К* (5) 
A plot of r/p]versus r (Scatchard plot) yields a straight line with 
intercepts nK and n. From equation 4 it follows that: 
Î = K[s] - пКГз] 
η ι + к [s] Ο Γ Γ 1 + К [S] 
or taking the reciprocal: 
I I J— . _L 
r
 =
 η
 +
 nK ' [S] 
(6) 
(7) 
A plot of 1/r versus l/[s] (Lineweaver-Burk plot (16)) yields a 
straight line with intercepts 1/n and -1/K. 
If there is more than one class of binding sites on the surface 
of the protein such that class 1 has η sites and an intrinsic asso­
ciation constant Κ. , class 2 has n. sites and an intrinsic association 
constant К , etc., then eq. 6 may be generalized as follows (17, 18): 
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r T = r l + r 2 + r l 
η К [S] η К [s] η К И 
1 1
 * . : I re > , : I
 m
 (β) 
ι + Kj [s] ι + κ 2 [s] ι + κ 1 [S] 
with r. being the average number of substrate molecules bound to 
class i. In fact, К is an apparent intrinsic association constant in 
which activity coefficients and electrostatic interaction terms are 
combined. A plot of rT/[S] versus г will now give a curved line. 
ANALYSIS OF BINDING CURVES 
If the experimental points do not yield a straight line, then the 
curve can be interpreted as being composed of two or more straight 
lines corresponding to different classes of binding sites. Rosenthal 
has described a graphical procedure to analyze such curves and to 
estimate the corresponding n- and K-values (19). We used these as 
starting values in our computerized curve-fitting procedure based on 
a gradient method for the non-linear parameter К and a linear regres­
sion method for the linear parameter η (20). In general, the choice 
of the number of classes of binding sites (binding model) with which 
the experimental results can be described is somewhat arbitrary. True, 
the presence of more than one class of binding sites can, provided 
that factors such as electrostatic, are constant or may be neglected, 
unambiguously be deduced from the deviation of the Scatchard plot 
from a straight line. However, the errors in the experimental data 
rarely allow a differentiation between a binding model with three, 
four or more classes of binding sites. In the analysis of our experi­
mental results the criterion for extending the number of classes was 
a statistical one, i.e. the number of classes were extended as long 
2 
as a significant decrease in the residual sum of squares, χ , occurred. 
The different models used are characterized and indicated by four 
digits, e.g. 312.2. The number of non-linear parameters, Κ., estimated 
by iteration is indicated by the first digit (i.e., 3 in the example). 
The number of those linear parameters, п., which were estimated by 
iteration is indicated by the second digit (i.e., 1 in the example). 
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The number of linear parameters with a chosen fixed integral value is 
indicated by the fourth digit (i.e., 2 in the example). The third 
digit gives the number of iteration terms; the terms in equation 8 in 
which the n. values are fixed are considered as one iteration term. 
ι 
If the value of the first digit is lower than the third, this indica­
tes the assumption of a partition term (or class with K.S << 1) in 
excess to the classes of binding sites. 
RESULTS 
BINDING CONDITIONS 
Typical results obtained from the binding experiments are shown in 
Fig. 2 as Scatchard plots for the binding of valerate to Povite albu­
min at 4 and 30 C. As appears from these curves, at least two classes 
of binding sites are involved in the binding. 
To investigate the influence of ionic strength on the binding, 
experiments were carried out with different salt conditions. This is 
demonstrated in Fig. 3 for the binding of valerate to albumin. The 
observed influence of the different anions on the binding of the 
valerate anion is compatible with the different affinities of the 
electrolyte anions for albumin (21). Since phosphate anions appear to 
interfere least with the binding of organic anions (21) it was used 
in all subsequent experiments. 
Since drug-receptor interaction is assumed to be specific, special 
attention was given to the binding of the fatty acid to the first, 
specific, binding site. Therefore it was essential to check whether 
the albumin used in the experiments was free from native fatty acids 
(22-24). To this end the binding of hexanoic acid to BSA from diffe­
rent manufacturers was measured before and after charcoal defatting 
(25). In Fig. 4 the results obtained with NBC albumin are shown as 
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50 
Fig. 2. Typiaal results obtained from dialysis binding experiments: 
Soatohard plots of the binding of valerate to untreated Povite 
albumin at 4 С (*) and at ¿О С (О). (Solution conditions: 
0.05 M phosphate buffer pH 6.9) The solid lines represent 
least squares fits to the experimental points based on equation 
Sj model 223.1 (see text). 
25 
IO 
•τ 
Fig. 3. Scctahavd plots indicating the influenae of type and concen­
tration of electrolytes on the binding of valerate to untrea­
ted NBC albumin at 20oC, pH 6.9. 0.1 M KCl О; 0.25 M KCl (Π); 
0.0b M phosphate buffer (χ). 
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Fig. 4. Scatahard plots indicating the influenae of charcoal defatting 
on the binding of hexanoate to albumin at 4 С The lines re­
present least squares fits to the experimental values, based 
on equation 8 model 222.0. The solid line is obtained with 
104 M'1 n, - 1.4 untreated NBC albumin; Kj - 2.5 (+ 0.3) 
(+ 0.1). The dashed line is obtained with untreated Povite 
albumin; Kj = 3.8 (+ 0.3) χ IO4 M' 1 12 = 1.9 (+ 0.1). The 
points indicate the results of one single experiment; (d) 
untreated NBC albumin; (m) charcoal defatted NBC albumin. 
(Solution conditions as in Fig. 2). 
Scatchard plots. The solid line represents the binding curve of hexa­
noate to NBC albumin; the dashed line represents the binding curve of 
Vis] ι ι^Μ"1) 
io 
'τ 
Fig. 5. ScaLchard plots indicating the influenae of aharcoal defaitine 
on -i-he binding of hexanoate to Povite albunin at 4 C. The solid 
lines represent least squares fits to the experimental points 
based on equation 8, nodel 222.0. (·) Untreated Povite albumin, 
batches 462 and 517; К 3.8 (+ 0.3) χ IO4 M 1 
Ч 
- 1.9 
(+_ 0.1), Ы) charooal-defatted Povite albunin, batch 577; 
K^ = 3.2 (± 0.2) χ 104 M-1, nj - 2.0 l± 0.1). (Solution condi­
tions as in Fig. 2). 
hexanoate to Povite albumin. From these curves it is evident that un -
treated Povite albumin binds stronger than untreated NBC albumin 
(Povite: Kj = 3.8 χ IO4 il ', ι = 1.9; NIÌC: К А -1 2 . 5 χ 1Ü M 
η = 1.4). The points, indicated in the figure, represent the results 
of one single dialysis experiment in which under identical circumstances, 
the binding of hexanoate to untreated NBC albumin is compared with the 
i' 
binding of charcoal-defatted NBC albumin. Clearly, the binding charac­
teristics of charcoal-defatted NBC albumin become identical to those of 
untreated Povite albumin. 
Fig. 5 shows the binding of hexanoate to untreated Povite albumin 
compared with the binding to charcoal-defatted Povite albumin. Evi­
dently, the binding characteristics of Povite albumin are affected by 
chartoal defatting only to a minor extent. From these results and 
those obtained with other fatty acids and some renal contrast media 
it was concluded that Povite albumin, contrary to NBC albumin, does 
not contain interfering lipid impurities. For this reason, if not 
otherwise stated, untreated Povite albumin was used in our experiments. 
ANALYSIS OF THE BINDING DATA 
Curves were fitted to the experimental points (e.g. solid lines in Fig. 
2) using equation 8 to describe the binding. The values for the para­
meters, n. and Κ., obtained from this curve fitting procedure depend 
on the number of classes of binding sites chosen to describe the 
binding. Table 1 summarizes, for the case of valerate, the different 
n- and K-values obtained from the different models used to describe 
the binding. Each model, indicated on a separate line in Table 1, is 
characterized by the four digits in the first column as was indicated 
above. In the next columns the values and standard errors for n. and 
th 1 
K. of the i class are given. The third column from the end gives the 
degrees of freedom, υ, in the curve-fitting procedure. The residual 
2 
sum of squares, χ , in the next column, is used as a measure for the 
goodness of fit. It can be compared with tabulated levels of signifi-
2 
canee, i.e. χ 5%. 
As appears from this table, the calculated K-values clearly depend 
on the model chosen. As far as the first class of binding sites is 
concerned, the product of η and Kj is, however, remarkably constant. 
So if the number of binding sites in the first class is fixed (e.g. 
on 1) a К -value is obtained which is practically independent of the 
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tabel 1 
Binding of Na-Valerate to BSA temperature 4°С 
model 
222 0 
233 0 
333 0 
344 0 
444 0 
223 1 
323 1 
334 1 
312 2 
323 2 
423 2 
n, 
1 3 6 ( 0 05) 
1 1 3 ( 0 051 
1 04 (0 071 
0 9 (0 2 ) 
0 9 (0 2 ) 
1 
1 
1 
1 
1 
1 
к, 
do* M 4 
3 3 (0 2) 
4 1 (0 2) 
4 5 ( 0 4) 
5 2 ( 0 9) 
4 9 ( 0 1) 
4 7 ( 0 1) 
4 7 (0 1) 
4 6 ( 0 1) 
4 6 ( 0 1 ) 
4 6 ( 0 1 ) 
4 6 ( 0 1) 
Πι 
5 2 (0 4) 
2 2 (0 2) 
1 6 (0 2) 
0 9 ( 0 3) 
1 0 ( 0 2 ) 
2 1 (0 1) 
1 5 (0 2) 
1 0 ( 0 4) 
1 
1 
1 
Кг 
(10* M ' ) 
0 0 1 4 ( 0 002) 
0 08 (0 02 ) 
0 15 (0.05 ) 
0 5 (0 5 ) 
0 4 (0 3 ) 
0 12 (0 01 ) 
0 18 (0 03 ) 
0 3 (0 2 ) 
0 32 (0 03 ) 
0 28 (0 03 ) 
0 29 (0 03 ) 
Пз 
0 0 0 7 8 ( 0 0007) 
9 (3 ) 
2 3 (0 5 ) 
4 (2 ) 
0 0085 |0 0006) 
9 (2 ) 
2 2 (0 6 ) 
6 3 (0 6 ) 
2 2 (0 6 ) 
4 (2 ) 
Кз 
(10* M ' ) 
0 0 0 1 6 ( 0 0009) 
0 0 2 (0 0 2 ) 
0 01 (0 01 ) 
0 0021 (0 0009) 
0 0 2 (0 0 2 I 
0 0052 (0 0008) 
0 018 (0 007 ) 
0 010 (0 005 ) 
П
А 
0 0 0 6 ( 0 001) 
0 6 (2 8 ) 
0 0 0 6 ( 0 001) 
0 0 0 6 ( 0 001) 
0 6 (2 5 ) 
K4 
(10* M ' ) 
0 002 (0 001) 
0 0 0 2 ( 0 001) 
υ 
54 
53 
52 
51 
50 
54 
53 
52 
54 
53 
52 
х
г 
136 
97 
66 
60 
59 
75 
66 
61 
74 
61 
60 
Χ
2
 5% 
72 
71 
70 
69 
68 
72 
71 
70 
72 
71 
70 
Different η- and ¡i-valúes obtained from the different models used to describe the binding of valerate to povite al-
bumin. Each model, indicated on a separate line in Table 1, is characterized by the four digits in the first column 
e.g. 312.2. The number of non-linear parameters, Ki, estimated by iteration is indicated by the first digit (i.e., 
3 in the example). The number of those linear parameters, n^, which were estimated by iteration is indicated by the 
socond digit (i.e., 1 in the example). The number of linear parameters with a chosen fixed integral value is indi-
catea by the fourth digit (i.e., 2 in the example). The third digit gives the number of iteration terms; the terms 
in equation θ in which the n,¿ values are fixed, are considered at one iteration term. If the value of the first 
digit is lower than the third, this indicates the assumption of a partition term (or class with K^S << 1) in excess 
to the classes of binding sites. In the next columns the values and standard errors for n-¿ and K-¿ of the i class 
are gijen. The third column from the end gives the degrees of freedom, v, in the curve fitting procedure. The resi-
dual sun of squares, χ , in the next coluim, is used as a measure for the goodness of fit. It can be compared with 
tabulated levels of significance, i.e. χ 5%. 
tabel 2 
Binding of fatty acids to BSA model 223 1 
fatty acid 
temperature 4° С 
Na-Propionate 
Na-Butyrate 
Na-Valerate 
Na-Hexanoate 
Na-Heptanoate 
Na-Octanoate 
temperature 30° С 
Na-Propionate 
Na-Butvrate 
Na-Valerate 
Na—Hexanoate 
Na-Heptanoate 
Na-Octanoate 
Пі 
1 
(10" M ' ) 
0 099 (0 004) 
1 1 1 80 (0 02 ) 
1 
1 
1 
1 
4 7 (0 1 ) 
6 8 (0 3 ) 
28 (1 ) 
164 (9 ) 
0 063 (0 005) 
0 83 (0 02) 
2 34 (0 08) 
3 2 (0 1 ) 
12 6 (0 3 ) 
62 (1 ) 
Ή 
0 9 (0 2) 
1 5 (0 1) 
2 1 (0 1) 
2 2 (0 2) 
3 3 (0 1) 
3 4 (0 4) 
1 (1 ) 
13 (0 2) 
2 3 (0 2) 
2 7 (0 2) 
4 6 (0 3) 
5 0 (0 3) 
K2 
(10" M ') 
0 027 (0 009) 
0 064(0 0081 
0 12 (0 01 ) 
0 30 (0 05 ) 
0 45 (0 08 ) 
10 (0 2 ) 
0 01 (0 01) 
0 06 (0 02) 
0 08 (0 01) 
0 19 (0 03) 
0 22 (0 031 
0 50 (0 04) 
Пз 
0 004 (0 001 ) 
0 0038 (0 0006) 
0 0085 (0 0006) 
0 018 (0 002) 
0 038 (0 004 ) 
012 (0 02 ) 
0 003 (0 004 I 
0 006 (0 001 I 
0 0093 (0 0007) 
0 017 (0 002 ) 
0 032 (0 003 ) 
0 10 (0 01 ) 
V 
14 
38 
54 
41 
38 
20 
14 
35 
35 
48 
33 
20 
x2 
1 
13 
75 
105 
118 
37 
4 
28 
48 
98 
43 
8 
X5 5% 
24 
53 
72 
57 
53 
32 
24 
50 
50 
65 
47 
32 
For explanation of the symbols see text table 1. 
tabelЭ 
Binding of fatty acids to BSA model 312 2 
fatty acid 
temperature. 4° С 
Na—Propionate 
Na-Butyrate 
Na-Valerate 
Na-Hexanoate 
Na-Heptanoate 
Na-Octanoate 
temperature. 30°С 
Na-Propionate 
Na-Butyrate 
Na-Valerate 
Na-Hexanoate 
Na—Heptanoate 
Na-Octanoate 
П, 
к, 
do" м ' ι 
0 1 0 4 ( 0 002) 
1 7 8 (0 02 ) 
4 6 (0 1 ) 
6 0 (0 3 ) 
26 (1 ) 
1 1 152 (6 ) 
1 
1 0 063 (0 005) 
1 0 83 (0 02 ) 
1 2 14 (0 08 ) 
1 | 2 9 (0 1 ) 
1 1 11 8 (0 5 ) 
1 1 62 (1 ) 
1 
n2 
1 7(0 1 ) a ) 
1 
K2 
do4 M 4 
0 0 1 4 ( 0 001) 
0 0 9 4 ( 0 009) 
ι ; 0 3 2 (0 03 ) 
| 
1 0 9 (0 1 ) 
1 2 3 (0 4 ) 
1 ι 5 2 (0 5 ) 
1 ' 0 0 1 6 ( 0 008) 
1 0 07 (0 01 ] 
1 0 27 (0 03 ) 
1 0 63 (0 08 ) 
1 1 2 (0 2 ) 
4 1(0 8 ) b ) 0 6 (0 1 ) 
1 
Пэ 
2 3 
6 3 
6 2 
9 8 
8 6 
3 
5 
7 6 
6 5 
9 7 
11 
(0 3) 
(0 6) 
(0 6) 
(0 7) 
(0 61 
(11 ) 
(3 ) 
(0 6) 
(0 6) 
(0 6) 
(4 ) 
«э 
ПО
4
 M 1 ) 
0 006 (0 002 ) 
0 0052 (0 0008) 
0 014 (0 002 ) 
0 025 (0 004 ) 
0 09 (0 01 ) 
0 0 0 2 (0 008) 
0 002 (0 0021 
0 004 (0 004) 
0 0 1 5 (00031 
0 030 (0 003) 
0 0 2 (0 02 ) 
υ 
15 
38 
54 
41 
38 
19 
14 
35 
35 
48 
33 
19 
Χ
1 
1 
14 
74 
56 
89 
13 
4 
28 
38 
77 
48 
8 
χ
2
 5% 
25 
53 
72 
57 
53 
30 
24 
50 
50 
65 
47 
30 
For explanation of the symbols see text table 1. 
a) oalculated with model 212.1; Ъ) oalculated with model 323.1. 
model adopted; moreover, this K.-value, representing the binding of the 
first fatty acid molecule to albumin, equals the so-called stepwise 
equilibrium constant defined by Fletcher (26) and can thus be consi­
dered independent of the binding of further fatty acid molecules. The 
experimental data obtained for the five other fatty acids were analyzed 
in a similar way as for valerate. The results obtained at 4 and 30 С 
2 
for the two most simple models which in general give reliable χ -values 
are summarized in Tables 2 and 3. Table 2 gives the results obtained 
with the model 223.1, i.e. two classes of binding sites with n. = 1 and 
a partition term. Table 3 gives the results obtained with the model 
312.2, i.e. three classes of binding sites with η = 1 and n, = 1. 
DISCUSSION 
Aqueous solution of hydrophobic substances show an apparently anomalous 
thermodynamic behaviour (27). The enthalpy of solution is contrary to 
what would be expected negative. This negative enthalpy change, how­
ever, is more than counterbalanced by a very large negative entropy of 
solution; this results in a positive standard free energy change and 
thus in a small solubility. This anomalous behaviour has been attri­
buted to an effect of the solute on the structure of liquid water (28). 
The binding of hydrophobic substances, and probably also of 
amphiphilic substances like fatty acids, to proteins can be considered 
as a partial reversal of the dissolution process (4, 28). The standard 
free energy of transfer, AG , (4) of the ligand to a protein-binding 
site can then be written as: 
Δ0 Ο = - RT In К = ΔΗ0 - TuS 0 (9) 
where К is the equilibrium constant for the binding site and ΔΗ 0 and 
33 
Δ8 0 are the standard enthalpy and entropy changes accompanying the 
binding process. If the hydrophobic effect dominates in the binding 
process, it is to be expected that ΔΗ and Δ3 will both be positive. 
From Tables 2 and 3 the affinity constants of the fatty acids for 
the first binding site on albumin, Κ., can be read. The dependence of 
the thermodynamic parameters, derived from this affinity constants at 
4 С and 30 C, on the alkyl chain length of the fatty acids provides 
information on the specific binding sites. 
-¿G=l?TlnK 1 
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Fig. 6. hG0 in Kaal for the binding of fatty acids, H(CH2)nC0Ó~ to 
Povite albumin plotted as a function of the chain length, и, 
at 4 C. (Solution conditions as in Fig. 2). 
Note the occurrence of the plateau at η = 4-5. 
In Fig. 6 ¿G at 4 С is plotted as a function of chain length; the 
black, circles represent the values of AG calculated from К ; the 
standard errors fall within the diameter of the circles. Evidently AG 
does not increase linearly with increasing chain length but a plateau 
is reached at η = 4 (valerate), and only at η = 6 AG further increases. 
The increment of AG per CH--group amounts to 1600 cai in the steepest 
part of the curve and 200 cai in the plateau. For the six fatty acids 
studied the mean increment per methylene group amounts to 820 cal. 
34 
Within experimental error, this value equals that of 825 cal, obtained 
by Tanford for the free energy change for transfer of undissociated 
fatty acids from a dilute aqueous buffer solution to liquid n-heptane 
at 23 С (4). This indicates, that the hydrophobic interaction of the 
alkyl chain of the fatty acid is quite optimal. 
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Fig. 7. The thermodynamie parameters àG y tjf, and ΔΕ? for the binding 
of fatty acids, Afí7fírJ„C00 to Povite albumin plotted as a 
function of the chain length, n. In the AG plot, (x) indicates 
the value at SO С and (·) the value at 40C. The bars indicate 
the standard errors. (Solution conditions as in Fig. 2) 
Note that the occurrence of the plateau in àG0 is independent 
of the model chosen to describe the binding. 
As can be seen in Fig. 7, the occurrence of the plateau in the AG0-value 
for the first binding site is independent of the binding model chosen. 
In this figure also the ΔΗ and AS values have been plotted as a 
function of n. The ΔΚ -value is negative and, except for the propionate 
anion, rather constant so that it seems to reflect predominantly the 
enthalpy change due to the binding of the carboxylic group. The Δ5 0-
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value is positive as has to be expected for a hydrophobic interaction 
(4). Seeing that it increases with chain length it probably reflects 
predominantly the entropy change due to the binding of the hydrophobic 
alkyl chain. 
The occurrence of the plateau in the plot of AG versus η can be 
interpreted in two ways: 
a. The binding site for fatty acids is built up from at least two 
hydrophobic binding areas. When assuming that the aliphatic chain binds 
in a stretched conformation, the extent of the first hydrophobic area 
is such, that it can accommodate a chain length of three or four carbon 
atoms. Fatty acids with an alkyl chain length exceeding the three to 
four methylene groups apparently come across a second hydrophobic 
binding area located at a distance of about two carbon atoms from the 
first one. 
b. Another way to look at the occurrence of the plateau is to suppose 
that we are dealing with two types of hydrophobic binding sites. The 
occurrence of the plateau then reflects the transition from binding of 
the fatty acids to the first type to binding to the second type of 
binding sites. 
To differentiate between these two possibilities competition 
experiments have been performed. Competition for a common first binding 
site can most conveniently be traced by plotting l/rT versus 1/ S 
(Lineweaver-Burk-plot). Fig. 8 gives such plots for the competition of 
butyrate and propionate for the first binding site of valerate. As 
appears from these plots the intercept on the 1/r -axis remains the 
same in the presence of the displacing fatty acid, butyrate or propio­
nate. Moreover, values of the affinity constants of the displacing 
fatty acids derived from the apparent decrease in the affinity constant 
of valerate, further referred to as displacement constants, equal, 
within experimental error, the values of the affinity constants 
obtained before, from dialysis experiments of the fatty acids alone 
(compare Tables 2 and 3). This indicates that these fatty acids do have 
their first binding site in common. The competition of hexanoate and 
heptanoate for the first binding site of octanoate displayed a similar 
picture, indicating that also these three fatty acids do have their 
first binding site in common. The competition of butyrate for the first 
binding site of octanoate is, however, much less effective and the same 
36 
Fig. 8. Lineweavev-Burk plots indicating the competition for the first 
binding site of valerate on Povite albumin. (*) without dis­
placing compound; (Ψ) in the presence of 10.6 χ 10 M propio­
nate; (£\) in the presence of 2.5 χ 10~^ M butyrate. (Solution 
conditions as in Fig. 2) 
holds true for the competition of octanoate for the first binding site 
of butyrate. Although some competitive displacement of butyrate by 
octanoate and of octanoate by butyrate occurs, the displacement con­
stants thus calculated are an order of magnitude smaller than the affi­
nity constants, obtained from dialysis experiments with the fatty acid 
alone. Evidently, octanoate and butyrate have not their first binding 
site in common. Probably, a second binding site of octanoate serves as 
a first binding site of butyrate and vice versa. Since propionate and 
butyrate do displace valerate with displacing constants about equal to 
their K. 's and hexanoate and heptanoate do displace octanoate with dis-
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placing constants about equal to their К 's, the picture emerges that, 
as supposed above in b., we are dealing with two types of hydrophobic 
binding sites. The first one, for short-chain fatty acids, can accommo­
date an alkyl chain with a length up to η = 4, and the second one, for 
long-chain fatty acids, can accommodate an alkyl chain as long as a 
heptyl chain. This second site, however, is less adapted to bind short-
chain fatty acids. 
CONCLUSIONS 
EXTENT OF HYDROPHOBIC BINDING AREAS 
From the results obtained in experiments with fatty acids alone and 
those performed in the presence of displacing fatty acids, one would 
conclude that the hydrophobic binding area, forming part of the first 
specific binding site for fatty acids on albumin, provides an almost 
optimal hydrophobic interaction possibility. For short-chain fatty 
acids this binding area seems to be limited in extent. This supports 
the representation given by Tanford (4). When assuming that the ali­
phatic chain is bound in a stretched conformation, the extent of this 
hydrophobic area has to be such, that it can accommodate a chain with 
a length of three to four carbon atoms. As far as the first binding 
site for long-chain fatty acids is concerned additional experiments 
will be needed to explore the extent of this hydrophobic binding area. 
The fact that this binding site is less adapted to bind short-chain 
fatty acids might be the consequence of an induced fit occurring on 
binding. 
From a comparison of our data with earlier work (Fig. 9), it now 
becomes obvious, that the data of Teresi and Luck (29) show the same 
tendency in having a plateau in AG at η = 6 to η = 4. The data of 
Goodman (30) and Spector et al. (31) for the binding of the longer 
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Fig. 9. Comparison of AG -values obtained from the present results with 
those from literature; (Ώ) present results at 4 C; (*) results 
from Teresi and Luak (29) at 2S0C, (o) Goodman (30) at 21°С, 
(Л) Speotor et al. (ZI) at 27 С. (The solution conditions are 
different) 
Note that the data of Teresi and Luak shew the same tendency 
in having a plateau at η = 4-5. 
fatty acids to albumin (Fig. 9) leave open the possibility for the 
occurrence of a second plateau. Differences in the absolute values of 
AG can be traced back to differences in solution conditions and 
purity of the albumin as has been demonstrated in Figs. 3 and 4. Also 
various pharmacological data (8, 9, 32) seem to indicate that the 
hydrophobic binding area cannot accommodate chains longer than 2 to 4 
carbon atoms. So it becomes tempting to postulate that lipophilic 
binding areas in the neighbourhood of polar groups on the protein in 
general cannot accommodate groups with a length of a carbon chain of 
more than four atoms. 
AFFINITY CONSTANT AND DISPLACEMENT CONSTANT 
From the competition experiments it became obvious, that it does make 
sense to differentiate, even in the case of closely related compounds 
like fatty acids, between the affinity constant obtained from the 
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binding of a drug to a certain protein and the displacement constant of 
the same drug deduced from a particular competition experiment with the 
same protein. In addition to competitive inhibition and non-competitive 
or allosteric inhibition a further possibility may be distinguished, 
viz. in which the drug shares its first binding site with a non-speci-
fic second or third binding site of the inhibitor. In that case the 
inhibitor displaces the drug competitively, although less effectively 
than would be expected on basis of the affinity constant of the inhibi-
tor for its own first binding site (33). Reversely, conclusions concer-
ning affinity constants deduced from displacement experiments (34, 35) 
need not to refer to the first specific binding site of the displacing 
drug. 
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SECTION It 
SPECIFICITY STUDIED BY NUCLEAR MAGNETIC RESONANCE 

Nonexponential Relaxation of the Methyl Protons of 
Acetrizoate in Solution 
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University of Nijmegen, Nijmegen, The Netherlands 
Received December 14, 1974 
The lime dependence of (he magnetization of the methyl group of acetrizoate 
dissolved in DiO is found to be strongly nonexponential. This effect is attributed 
to the induencc of cross-correlations and is in nice agreement with the theory of 
Hubbard and its extended form presented by Werbelow and Marshall. The rotational 
diffusion of the methyl group around its axis is estimated to be 30 times as fast as the 
overall rotation of the whole molecule. In the presence of BSA the nonexponential 
relaxation effect disappears. Inaddmon it is shown that, fora symmetric top molecule 
with the axis of the methyl group along the molecular symmetry axis and the methyl 
group rotation in the extreme narrowing limit, analytical expressions can be derived 
for the time decay of the magnetization, when the rotation of the molecule 
perpendicular to this axis is not in the limit ofextreme narrowing. There is, however, 
a lower limit to the rale of this motion. 
INTRODUCTION 
Recently a number ofpapers have been devoted to the study of the relaxation behavior 
of methyl groups (/-4). In particular the possible influence of cross-correlation has 
aroused some attention since tt may give rise to a nonexponential relaxation pattern. 
This effect will only become manifest when the overall motion of the methyl group is 
highly anisotropic (/, 2, 4) and may therefore be of potential interest to protein and 
membrane studies. It can, however, be masked by other mechanisms like intermolecular 
dipole-dipole and spin-rotation relaxation. Nevertheless, since cross-correlation terms 
will always be present when the spin system consists of three or more rigidly fixed 
spins (rigidly fixed with respect to each other), it should be quite a general phenomenon. 
The effect has been observed in solids (5, 6), but it is somewhat surprising that in 
solutions it has only been measured m a few rare instances (6, 7). There is even some 
confusion m one case whether indeed the observed nonexponential relaxation should be 
attributed to cross-correlation effects (4, 6), while in the other case (7) the effect is 
largely masked by spin-rotation relaxation contributions. This would imply that the 
cross-correlation terms are apparently small or not very important. 
During the course of our investigation of the binding of the renal contrast medium 
acetrizoate to serum albumin, we found that the methyl group of the acetrizoate 
exhibited a pronounced nonexponential relaxation behavior. In this molecule the effect 
of the cross-terms clearly becomes manifest and it is anticipated that acetrizoate is 
• Department of Pharmacology. 
t Department of Biophysical Chemistry. 
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representative of a large class of molecules exhibiting nonexponential relaxation 
behavior. 
EXPERIMENTAL 
Theacetrizoateftriognost^) used in these experiments was kindly supplied by Draga 
(Draga, Diemen, The Netherlands). Bovine serum albumin (BSA) was purchased from 
Povite (Povitc, Amsterdam). All other materials were obtained from Merck. Acetrizoate 
was dissolved in D 2 0 containing 0.1 M KCl, 0.05 M phosphate buffer, at pH 7. 
The relaxation measurements were carried out with a Varian XL-100 instrument 
equipped with FT facilities. For the Γ, measurements a l80°-f-90° pulse sequence was 
used. The Tj relaxation times were determined as T,,,, using an adiabatic half passage 
into the center of the resonance line {8). The measurements were conducted at 30-34°C. 
RESULTS AND DISCUSSION 
A representative example of the nonexponential relaxation (NFR) eiTect, which can 
be detected m acetrizoate solutions, is shown in Fig. I, where the magnetization of the 
methyl group is plotted as a function of time. Added is also the time dependence of the 
ring proton magnetization, which is an exponential function of time. The latter observa-
2 4 6 б 10 12 Ш 16 18 20 
time (вес) 
FIG. 1. Longitudinal relaxation of the ring proton (ФН) and methyl group of 0 I .Vf acetrizoate 
dissolved in D20, phosphatc-KCI bulTer, ionic strength // = 0 2, pH = 7 0, at 32 С The points are 
experimental, the line drawn for the methyl group relaxation is calculated according to Eq. [I] with 
parameter values A[ = 0.14, А'
г
 = 0.86; Í , = 0.09 and а
г
 = 1.34. 
tion rules out the possibility that nonlmeanties in the detector system are causing the 
nonexponential time dependence of the methyl group magnetization. 
The Г, relaxation of the methyl group was measured at two dilTerent concentrations 
of acetrizoate (see Table I). Also the influence of bovine serum albumin (BSA), added' 
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TABLE 1 
RELAXATION PARAMETERS OF THE ACETRIZOATE METHYL GROUP 
Acetnzoate 
concentration 
BSA 
concentration 
Type of 
relaxation 
St 
- * j 
Ζ 
О 
ζ 
m 
χ 
S 
s 
ζ H 
? 
r 
je 
m 
r 
δ 
ζ 
о 
н 
χ 
>< 
r 
•8 
JO 
О H 
о 
ζ 
1 χ ΙΟ"1 ЛГ 
5 χ IO"3 
5 χ IO"3 
Г, (a) 
Τ, (a) 
Τ",» (a) 
0.104 0.004 0.012 0.001 
0 070 0.007 0 009 0.003 
0.071 0.002 0.019 0001 
5 χ IO"3 
5 χ IO"3 
5 χ IO"3 
5 x IO"3 
5 χ IO"3 
1 χ ΙΟ"5 M 
3 χ IO"5 
1.5 χ IO"5 
3 χ IO"' 
5 χ ΙΟ"5 
Ά, 
Τ,α 
Γ, 
Ά 
τ, 
0.14 
0 19 
0.14 
0.11 
0.12 
0.12 
0.11 
0.03 
0.14 
0 12 
0 
0 003 
0.03 
0.01 
0.09 
0.003 
0.02 
0.03 
0.03 
0.08 
0.24 
0.03 
0 09 
0.12 
0.06 
0.07 
0.14 
0.14 
0.18 
0.33 
0.07 
0.14 
0 009 
0.02 
0.02 
0.08 
0 005 
0.03 
0.05 
0.10 
0 09 
0.38 
1.3 
1.47 
0.9 
0.9 
1.0 
1.0 
1.3 
1.0 
0.97 
0.94 
0.99 
0.05 
0.09 
0 07 
0 14 
0 02 
0.04 
0 06 
0 03 
011 
0 26 
0 03 
" These experiments were fitted in two ways The upper values of each experiment were obtained by iteration of У and J" to the experimental points The 
lower values were obtained by direct iteration of A¡, s¡ and jj. 
σ = standard error in calculated values x. 
to the solutions, was studied With increasing concentrations of albumin the non-
exponential relaxation effect of Γ, as well as TXl¡ decreases and at 5 χ ΙΟ"5 Λ/ BSA it 
disappears This is demonstrated in Fig 2, where the 7",p behavior of the acetrizoate 
methyl group has been plotted for different BSA concentrations It is noted in passing 
that this experiment provides additional proof that the NER effect is not an instru­
mental artifact 
The effect of the cross-correlation between the motion of the protons within a given 
methyl group has been extensively studied by Hubbard (У, 2), who showed that in the 
( l « ) t 
( I z ) s i n e 
FIG 2 The transversal relaxation of the methyl group of acetrizoate, determined as 7", „, as a function 
of BSA concentration · [BSA] = 0, χ [BSA]= ΙΟ"5 Μ, о [BSA] = 3 χ ΙΟ"' M The lines drawn were 
calculated according to Eq [I ] with the parameters given in Table 1 
limit of extreme narrowing the time dependence of the longitudinal as well as the trans­
versal magnetization can be described by two exponentials, ι e , 
R(t) = A[e,s + A'1e>*\ [1] 
where R(t) = «/,> - </
г
>г)/(<:о5 0 - 1)</2>T after a 0 pulse has been applied to the spin 
system, </j> stands for the longitudinal magnetization and <II")T is its thermal equi­
librium value In case the transversal magnetization time decay is measured /?(/) = 
</I>/sin9</I>
T
 with </,> being the transversal magnetization The constants character­
izing the relaxation are related by the following expressions 
Al1=\-A
,
l. [2] 
and 
Л'х = -И' - И·/' + (5/2)У][ЗбУ'г + (45/4).ГЧ-" 2} 
Furthermore 
5
' | = -6У'-(15/2)7" ± [367' 2-Ι-(45/4)7" 2]" 2 [3] 
¡ι) 
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The parameters У and./ ait funclions of the molecular diffusional constants When 
the molecule has arbitrary shape, the expressions for these parameters are quite com­
plicated If, however J <^J it can be deduced from hqs [2] and [3] that / 4 , ' A ¿ , 
A 2 ~ I and | ν, | <^  |\ ; | with \1 approaching zero The inequality У 4 J 'holds whenever the 
rotation of the methyl group is rapid with respect to the rotational Brownian motion of 
the molecule, while the latter motion is supposed to be fast with respect to the Larmor 
frequency (2) 
The values of the parameters s,, s2. A, and A2 in Table I (in absence of BSA) and also 
the curves, drawn m f igs I and 2 (absence of BSA) for the methyl relaxation, were 
obtained from J and J The latter two parameters were obtained by fitting the time 
dependence of the magncli/ation (Eq [I]) to the experimental points through iteration 
When BSA was present in solution, the time dependence of the magnetization was fitted 
to the experimental points by a direct iteratioTi of j , , v2, ΑΊ and to their final values 
assuming no other relationship between j , , f2,/li and/ij than/1Í = I —/li Thestandard 
errors of they' and J" and/or A1, y^jj are also given in Table I In absence of BSA 
comparison of A¡, J, and s2 with their standard errors demonstrates the significance 
of the nonexponentidlity m the magnetization decay within one experiment Inspection 
of Table 1 shows that the values obtained for the acetrizoate methyl group agree 
within the variation between the experiments with those predicted by Hubbard (2) 
fora molecule of arbitrary symmetry withy <^  У As stated above, these latter para­
meters are difficult to interpret in terms of molecular rotations Therefore we estimated 
the magnitude of the diffusion constants by assuming that the molecular motion was 
that of a spherical molecule on which the rotation of the methyl group around its 
axis is superimposed In that case the three molecular rotational diffusion constants 
are equal (Z>)and the expressions for У and У simplify (2) to 
У = Cj(6û) [4] 
and 
У = 3C/(v' + 6Û) [5] 
with v' = 4Db where D, is the rotational diffusion constant characterizing the rotation 
of the methyl group around its axis The constant С = (3/40)(}>2/î/r3)2and; is the distance 
between the protons in the methyl group In the calculations below we used r = I 80 A 
For the values оГУ' and У given in Table I, Z), and D were calculated and tabulated m 
Table 2 As expected the rotation of the methyl group around its axis is indeed much 
faster (about 30 times) than the rotation of the whole molecule However, the value of 
TABLE 2 
ROTATIONAL DIFFUSION CONSTANTS 
Acetrizoate 
concentration 
Ι χ ΙΟ"' M 
5 χ IO"3 
5 x IO"3 
D 
rad2 sec- 1 
1 5 χ 10* 
2 3 x 1 0 ' 
2 2 χ 10' 
o, 
rad2 sec"1 
58 χ 10* 
77 χ 10' 
34 χ 10' 
Type of 
relaxation 
T, 
Ά 
Tin 
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D = 2 χ IO4 rad 2 sec - 1 , which ¡s not too diflerent from the Larmor precession frequency 
Шо = 2π χ 10s. 
Recently Wcrbelow and Marshall (4) extended Hubbard's theory to the case where 
the limit of extreme narrowing is no longer valid. In this situation the time dependence 
of the magnetization is described by the sum of three exponentials: 
R(t) = Л,«?*" + А
г
е
1
^ + А^' [6] 
For a symmetric top molecule, with the axis of the methyl group along the molecular 
symmetry axis, the authors designed contour plots exhibiting the preexponenlial 
factors Ai and the ratios of the time constants A,/Aj as a function of the rotational 
diffusion constants. 
More detailed plots of the longitudinal relaxation parameters for regions of the 
rotational diffusion coefficients relevant to the present problem, were constructed and 
are given in Fig. 3. These show some interesting features. 
When £)±hasa valuccharacteristicoftheextremenarrowinghmitand Dl + Dt i> D , 
where D, is the diffusion constant parallel and Dj that perpendicular to the molecular 
symmetry axis, the longitudinal relaxation parameters take the following simple 
form: AiX ^\ A2~ і;А3х% and ¡Α,Ι <^  |л 2 | with Я, approaching zero. These results are 
obtained even when Dl is not representative of the extreme narrowing limit. When it is, 
but remains sufficiently small with respect to /)„ + D¡, the time constant / 2 a A3 and we 
obtain the same constants as were calculated by Hubbard for a molecule of arbitrary 
symmetry with J" <4J', discussed above, so that A¡ = Αι; ΑΊ = Aj + А3; ν, = /, and 
Í2 = ¿2 = ¿э- In the Appendix it will be shown that these observations can be cast into 
an analytical form. Independently of Hubbard's model, the first three experiments in 
Table 1 can be fitted with a two-exponential function and this yields preexponential 
factors and time constants which are close to those obtained by fitting У and У". 
Using the average values of these first three experiments m combination with Fig. 3, 
we estimate ( D , + £>,) = 7 χ IO1 0 rad2 sec"1 and D, = 2 χ IO9 rad2 sec '. Thus both 
models give diffusion constants in reasonable agreement with each other, while 
А'г = А
г
 + Ai with А
г
 = 0.3 and А3 = 0.6. On the other hand, taking the radius of the 
iodobenzene group equal to 5 6 A yields a value of the rotational diffusion constant, 
characteristic of the rotation of the whole molecule, of D — 9.3 χ 10я rad 2 sec"', 
calculated on the basis of the Stokes-Emstein model This again is close to the values 
given in Table 2. Thus it is anticipated that the methyl group relaxation of molecules 
with a radius of about 6 Ä and higher (see Appendix), will be strongly nonexponcntial, 
provided that spin-rotation and mtcrmolecular relaxation contributions arc not im-
portant and the rotation of the methyl group is not hindered too strongly In the present 
experiments the mtermolecular relaxation was suppressed by carrying out the measuie-
ments in D2O and the spin rotation contributions were estimated to be smaller than 
1 % (9). 
In the presence of USA the NLR effect disappears (see Fig 2 and Table I) Seveial 
mechanisms may be responsible for this result. If the rotation of the methyl group is not 
FIG 3 Contour plots of the prccxponcntul faciors .1, and the evponcmials /., of die longuiitlinal 
relaxation as a function of /) and!/) 1 D,) haul Lontoin is a line ol constant maynitude of the in-
dicated relaxation parameter The caluilatmns lia\e heen performed foro,, = 2 π χ lü" as ihc Larmor 
precession frequency. 
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affected upon binding of acelrizoate to the protein molecule, one would expect the 
relaxation to remain strongly nonexponential (see Appendix). If, on the other hand, 
the rotation of the methyl group is immobilized to the same extent as the acetrizoate 
molecule, the NER effect may disappear. Also protons of the BSA molecule may con­
tribute to the relaxation of the methyl protons and obscure the nonexponential 
behavior. Most probably, however, chemical exchange terms will dominate the relaxa­
tion and mask the NER effect. The binding of triognost to BSA is rather involved, 
because of the existence of several binding sites wilh different binding constants (/0) 
and therefore we shall not elaborate on this any further. 
APPENDIX 
The differential equations determining the time dependence of the longitudinal 
magnetization of a spin system of three identical spm-i nuclei at the corners of a 
equilateral triangle are given by (/): 
dyjdt = -[2J
a
{io0) + 8Λ(2ω0) + l/ r(W [ ))] y^t) 
+ [-12У
г
(
Шо
) + 24У
с
(2а)о)]>'
г
(0 
+ 16[Л(
Шо
)-У
с
(2шо)]^(0, [Al] 
dytldi = (*)[/.(ωο) - 4У.(2шо) - Λία*,) + 4У
г
(2<а0)]>1(/) 
- [ЗУ
а
(0) - У.(
Шо
) + 2У
в
(2ш0) - ЗУДО) + Уг(ш0) - иДТа^уМ) 
+ (і)[6У
а
(0) - 10Λ(ω0) + 4Λ(2ω0) - 6УГ(0) + ЮУДсоо) 
-4У
с
(2ш0)]^(0, [А2] 
dy3ldt = [Уо(и>0) - 2У.(2шо) + Л(а>о)] ƒ і(/) 
+ (ΜΛ(ωο) + ЗУДшо) + І2УД2шо)]>'2(/) 
- [9У.(ш0) - Jc(ω0) + 4У,(2Û»O) W / ) . [A3] 
where y\(t) = Tr[x(r)/r] = </Л - (/j)7"; </I^ is the longitudinal magnetization and 
(/,) 7 the thermal equilibrium value of/,, while χ(ΐ) represents the appropriate density 
matrix, y^t) and .Гз(/) are the other combinations of matrix elements (see (/) and (4)). 
JcikiOo) is the spectral density of the autocorrelation function and У
г
(/гш0) that of the 
cross-correlation function. Hubbard showed (/) that in the limit of extreme narrowing, 
Eqs. [Al] and [A2] are no longer coupled to [A3]. The system of differential equations 
also considerably simplifies when J
a
(kw0) = Jc(kœ0) =/(kw0). In this case Eq. [A2] 
reduces to dyjdi = 0 and the time dependence of the longitudinal magnetization is 
found to be: 
Ä(0= i+ іе-і2Пш°и+ , ρ - ' ^ ω ο π . [A4] 
Using the differential equations characterizing the transversal magnetization (4) we 
obtain, under the conditions that У„(А'ш0) = Jr(k,œ0) = I(ka>0), for the time dependence 
of {he transversal magnetization: 
O(t) = i + ìe-6^"0>+'<шo'J^ + А
е
-ьіішо)+И2ш0)]і \A5] 
In the limit of extreme narrowing /(0) = /(a>o) = /(2ωο) and as expected [A4] and [A5] 
become equal and the time dependence of the longitudinal and transversal relaxation 
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reduces to that described by Hubbard (2), i e , the parameters of Eq. [1] become 
^i' = ¿ .^2 = 1 a n d st = 0· 
In general it is not easy to show under which circumstances /„(/CCÜQ) = J^kajg). For 
a symmetric top molécule, however, with the axis of the methyl group along the sym-
metry axis of the molecule, the following relations can be derived (4): 
r(,r„\-r\ 6D± ! 3[2PL + 4 ( u , + g,)] \ Á 0)
 - \((>D±y + (kœ0)> + [2О± + Л(В, + П^ + (ксо0г1 [АЬІ 
and 
. / Д К о 0 ) - С | ( 6 ^ ) 2 + О Ы о ) 2 2 [ 2 D ± + 4(Dt + Dt)]2 + (küJo)2] lA/J 
If the second term within the brackets, "(kw0)IC in [A6] and —¥(kü)0)IC in [A7], can 
be neglected with respect to the first term, '(ка>о)^
а
(ка>0) equals Jc(ka)0) This condition 
is met, when the following relations hold. 
(i) {Di + DiibD^fraJo), 
(n) (Di+D,)D±>(kai0)2. 
The present analysis shows that whenever the rotation of the methyl group around its 
axis is in the extreme narrowing limit and much faster than the rotation of the molecule 
perpendicular to this axis, the methyl group relaxation can be described by Eqs [A4] 
and [A5] These even apply when the molecular rotation, characterized by D±, is not 
in the extreme narrowing limit. There is, however, a lower limit to £»L given by 
condition (n) 
Expressions [A4] and [A5] are of practical importance for protein and membrane 
systems, provided the rotation of the methyl group is relatively unhindered and the rota­
tion of the molecule is relatively slow, since proteins often are globular in nature and 
the effective motion of molecules in a membrane often resembles that of a symmetric 
top molecule 
Interestingly the initial slopes of R(t) and Q(t) (Eqs [A4] and [A5]) are given by 
dR(0)ldt = -2/(ω 0 ) - 8/(2ω0) 
and 
dQ(0)/dt = -31(0) - 5Ι(ω0) - 2/(2ω0). 
Since /(Αω0) — 70(Αω0) these slopes are just equal to those obtained when the influence 
ol cross-correlation is disregarded (II). 
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INTRODUCTION 
Protein binding of drugs, in particular drug-albumin binding, can in-
terfere with a number of biophysical processes in the body (1, 2, 3). 
It may for instance have a profound influence on the pharmacokinetics 
of the drug involved. Two factors are important in this respect. First 
the amount of drug bound to the protein, determined by the affinity 
constant and the concentrations of protein and drug, since albumin-
bound drug is not susceptible to ultra filtration and to diffusion 
processes occurring for instance in kidney, liver, brain, etc. (4, 5). 
Moreover, in general the fraction of bound drug will not be directly 
involved in drug action (2). On the other hand the drug-protein com-
plex can serve as a drug depot i.e. release of the drug from the com-
plex will tend to maintain the free drug concentration (4, 6). This 
constitutes the second factor of importance, the dissociation rate of 
the drug-protein complex, which may affect the active transport pro-
cesses e.g. in kidney, liver and brain. 
Dynamic events occurring during protein-drug binding can be stu-
died by magnetic resonance techniques. Exchange of the drug molecules 
between protein and solution may cause shifting and broadening of the 
nmr signals (7, 8, 9). The linebroadening and shifts are determined by 
three independent parameters: i) the relaxation time of the drug mole-
cule when bound to the protein, ii) the exchange rate, and iii) the 
difference between resonance frequencies of the protons of the drug 
molecule when bound to the protein or free in solution. 
In the present paper the binding of the renal contrast medium 
acetrizoate (Triognost ) to bovine serum albumin has been studied 
by proton magnetic resonance. In relation to its renal tubular excre-
tion it is of interest to know whether the dissociation rate of the 
acetrizoate-albumin complex is rate limiting in the active excretion 
process (10, II). Moreover, the strong binding of acetrizoate to al-
bumin compared to the weak binding of other contrast media of the 
tri-iodo-benzoic acid family (10) leads one to wonder as to what part 
or group of the acetrizoate molecule may be responsible for the 
rather specific and strong binding of acetrizoate to albumin. 
Acetrizoate seemed to be particularly suited for a nmr study 
because of the simplicity of its nmr spectrum and because according 
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to Lang and Lasser (12) binding predominantly takes place at one site 
on the albumin molecule. During the course of this investigation it 
became evident from nmr as well as from independent dialysis binding 
studies that there are at least two groups of binding sites on the 
albumin molecule. In spite of this complication the dissociation rate 
of the different type of complexes could be estimated by combining nmr 
and equilibrium dialysis experiments. It can also be derived from the 
present and other investigations that the interpretation of earlier 
nmr studies of pharmacologically interesting systems may be over­
simplified. 
EXPERIMENTAL 
The acetrizoate (Triognost ) used in the nmr as well as the dialysis 
experiments and the starting material (2,4,6-tri-iodo-3-amino benzoic 
14 . . 
acid) for the С -labelled acetrizoate were kindly supplied by Dagra 
(Dagra, Diemen, The Netherlands). Bovine serum albumin (BSA) was pur­
chased from Povite (Povite, Amsterdam). All other materials were ob­
tained from Merck, Darmstadt, Germany. 
cooH 
Acetrizoate 
14 
Acetrizoate-C was synthesized by adding 40 mg of 2,4,6-tri-iodo-
14 3_amino benzoic acid to 4 mg acetic anhydride-1-C , which had been 
dissolved in 5 ml acetonitrile under exclusion of air. The acetoni-
trile was freshly distilled from P-jOci SO. was used as a catalyst. 
The radiochemical purity was checked by taking an autoradiogram of a 
kieselgel dunnschicht chromatogram, developed in a solution of ben­
zene, ethanol, acetic acid in the ratio 7:1:2. 
The binding of acetrizoate to albumin was determined in equili­
brium dialysis experiments at 4 and 30 С by measuring the radioacti-
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vity of the acetrizoate-C , present in tracer amounts in the samples, 
on both sides of the membrane (13, 14). The samples were prepared by 
dissolving the required amounts of acetrizoate and albumin in H.O 
containing 0.1 M KCl, 0.05 M phosphate buffer, while at pH 7. The nrar 
samples were prepared in D O , the solutions were of the same composi-
tion and pH as those used in the dialysis experiments. 
The nmr experiments were carried out on a Varían XL-100 instru-
ment equipped with F.T. facilities. The spectra were obtained either 
by accumulation in a Varían C1024 time average computer or by accumu-
lation using the F.T. technique. In the latter case a (180O-t-90O-T) 
pulse, sequence was used in order to avoid dynamic range problems, 
connected with the limited wordlength of the computer memory, due to 
the residual HDO resonance (15). Samples were freshly prepared just 
prior to the measurements. 
THEORETICAL BACKGROUND 
As will be shown in the next section to a good approximation the bin-
ding of acetrizoate to BSA can be described by two classes of indepen-
dent identical sites on the albumin molecule. Exchange of the acetri-
zoate molecules bound to the protein and free in solution results in a 
transfer of magnetization between three different environments. The 
transition probabilities between these states can be defined as 
follows : 
N 
j = l 
all configurations 
riS - ki : TÜ " kI ^.« і*! 
(1) 
N 
all configurations 
where к and к are the dissociation rate cnnst.ints for the complexes 
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of the type I and II and к and к are the corresponding association 
rate constants, defined by the following reaction equation: 
PS. . + S . ^ PS. (2) 
J
" k + J 
PS. is a particular configuration of j molecules S bound to a certain 
class of binding sites on the protein molecule. The ^ signs indicate 
a summation over all particles PS. and over all their configurations 
present in solution. The definitions in eqs. 1 implicitly assume that 
binding to the sites takes place independently and that the sites 
within a class are identical. Moreover, it is assumed that no direct 
exchange takes place between the binding sites of class I and II. 
The dissociation and association transition probabilities are 
related by the following equation: 
ρ 
-! 0 - -1 ... 
T
si - rs] ri Tis (3) 
where r. represents the average number of acetrizoate molecules bound 
per albumin molecule for a particular class, i, of binding sites; P. 
is the concentration of protein weighed into the sample and [s] is the 
concentration of free substrate molecules. Within the approximations 
mentioned above i.e. independent and identical binding sites, the 
average number of molecules bound per albumin molecule for particular 
class of binding sites is given by (13, 16) 
n.K.[s] 
r i = ι I K - L S J ( 4 ) 
where K. is the equilibrium constant characterizing reaction equation 
2 and n. is the total number of sites of the class i available for 
binding. The total average number of acetrizoate molecules bound to 
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BSA i s : 
I I 
n iK iC s^ n i i K i ¿ s J 
1 + KjCS] 1 + K ^ S J (5) 
The пшг experiments were carried out with a large excess of sub­
strate molecules so that using the eq. 3, the dissociation rates can 
be directly related to the observed linebroadening (17): 
„-1 
- Τ 
ΓI 
2S Г
Л
 + rii xii (6) 
where T- equals ττΑν, with Δν, being the observed linewidth at half-
height of the substrate resonances in the presence of protein. T_ is 
the reciprocal transversal relaxation time of the substrate resonance 
in the absence of protein. S» is the concentration of substrate 
weighed into the sample. The linebroadening parameters X and X are 
concentration independent. They are a function of the dissociation 
rate constant, τ.., the relaxation rate of the nucleus in the substrate 
-1 
molecule while bound to the protein molecule, T,.., and the chemical 
shift difference Дш. between the resonance position free in solution 
and bound to one of the sites of class i, i.e. (17, 18): 
X. 
ι 
l i S 'is τΐί(i + \s т;і> + ( А Ш І T i s ) 2 
(1
 + T . S T ¡ ! ) 2 + (Дсо. T i s ) 2 
(7) 
In an analogous fashion the observed changes in the resonance 
positions are related to the binding parameters by (17): 
Γ
ι
Δ
ι
 + Γ
ιι
Δ
ιι 
(8) 
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with: 
Δω. 
Δ = - ^ 2 (9) 
(1
 +
 x i s Τ 2 ! )
2
 +
 (Δ.. x i s )
2 
In practice expressions 7 and 9 can often be simplified. Recent­
ly Granot and Fiat (19) have systematically reviewed the possible 
simplifications of eqs. 7 and 9. These results will not be reproduced 
here, but for the readers convenience those limiting cases employed 
in the following sections will be given. 
Case I: 
Complexation of acetrizoate to the specific binding site on al­
bumin resulted in zero values for Δ (see Results Section). Under 
these circumstances the following conditions apply: 
Δω. << T„. or Δω. « 0 
ι 2ι ι 
i.e. equations 7 and 9 can be simplified to: 
x. = (Xis-T,.)-1 (.0) 
and 
Ai " Лші \s (ÏÏS + ^ l · " 2 <"> 
Δ. approaches zero when Δω. approaches zero and/or τ.„ is much larger 
ι ι iS 
than T... 
2i 
Case II: 
For the binding of acetrizoate to the second class of binding 
sites we have no clue as to the relative values of T„. and Δω·. We 
2ι ι 
61 
will therefore start out to assume that ûto.iiî T„. . Since the tempera-
i 2i 
ture dependence of the linebroadening indicates the existence of a 
2 
fast exchange situation i.e. (Δω. ?·„) < < 1» eqs. 7 and 9 can be 
written as: 
x i - ( T i s + V"1 + 4 T is <' + T is T¡l ·"2 (,2) 
and 
A i • Δ ω χ <· + T i s т ; ! > ~ 2 ( І З ) 
-] 2 
Since in the present circumstances (χ. T_.) << 1, these equations 
can be simplified to: 
X. = (Δω. + Δ)(2Τ„ Δω.)"' + x.„ Δ. Δω. (14) 
ι ι 2 ι iS ι ι 
and 
Δ. = Δω. (1 - 2T. S T¡!) (15) 
Fast exchange conditions applied to the limiting cases where 
T-. << Δω. or T„. >> Δω. lead to formulae, which are not compatible 
2ι ι 2ι ι 
with the observed linebroadenings and shifts. 
RESULTS 
A. CONCENTRATION DEPENDENCE 
An example of the linebroadening observed for the acetrizoate reso­
nances as a result of binding to albumin is shown in Fig. 1, The 
lower half of the figure displays the spectrum of a 6 χ 10 M ace-
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trizoate solution without albumin, the upper half of the figure was 
recorded with 2.4 χ 10 M albumin present in the sample. 
~J^ -
L 
Hz 000 640 wo 320 160 
Fig. 1. NMR spectra of aaetrizoate (6 χ 10 M) in α Ό20-phosphate 
bufferj pH = 7.4. Lower spectrum without, upper spectrum with 
albumin (2.4 χ 10~5 M). The resonances at 58, 160, 260 and 
780 Hz were recorded on an expanded scale and at a higher am­
plification factor and inserted at their corresponding fre­
quencies . 
The intense signal at about 430 Hz is due to residual HDO. The re­
sonances of interest, at 58, 160, 260 and 780 Hz respectively, were 
recorded on an expanded scale and at a higher amplification factor and 
were inserted in the figure at their corresponding frequencies. Pro­
ceeding from left to right they represent the φ-Η of acetrizoate, the 
methylgroups of tetramethylammoniumchloride (TMAC), the methylgroup of 
acetrizoate and the methylgroup of t-butylalcohol. The methylresonances 
of tetramethylammoniumchloride and t-butylalcohol served as a check on 
the field homogeneity and as internal references. Addition of albumin 
clearly shows a linebroadening of the acetrizoate resonances while the 
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reference signals remain virtually unchanged. For a series of solutions 
with constant acetrizoate concentration, S
n
, but increasing BSA concen­
tration, Ρ
η
, the linewidths were measured. Chemical shift changes, 6, 
were determined with respect to TMAC. In all samples acetrizoate was 
present in large excess. The data thus obtained were plotted as a func­
tion of P 0/S n. In Fig. 2 such a plot of T. as function of PQ/SQ is 
presented, for the CH, and φ-Η resonances of acetrizoate, while in Fig. 
3 analogous plots of δ are given. 
Fig. 2. Plot of Tg of the ф-Я and СИ, protons of acetrizoate as a 
function of the ratio of the amount of protein and substrate 
weighed into the sample. The acetrizoate concentration was 
kept constant at 3.5 χ 10~3 M. Each point is an average of at 
least six independent linewidth measurements. Temperature 30°С. 
The solid lines represent least squares fits to the experimental 
points based on equation 6. 
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δ Hz 
?Ü9 
93 
2 4 6 12 
κ ΙΟ'
2
 Ρ0/50 
Fig. 3. Plot of ahenríoal shift values, δ, of the ф-Я and CH? protons of 
aeetrizoate as a function of the ratio of the amount of protein 
and substrate weighed into the sample. Each point is an average 
of at least six independent shift measurements. Aeetrizoate 
concentration 3.5 χ 10~г M. Temperature 30oC. The solid lines 
represent least squares fits to the experimental points based on 
equation 8. 
As expected on the basis of eqs. 6 and 8, Ί and & linearly increase 
with increasing BSA concentration. 
Before an interpretation of the slope of the lines in Fig. 2 in 
terras of exchange and relaxation phenomena can be given, it is necessa­
ry to show whether the broadening is due to specific or multiple bin­
ding. To this end a series of experiments, like those given in Fig. 2, 
were conducted with varying aeetrizoate concentrations. The slopes of 
the lines, tg a, obtained in the individual experiments, turned out to 
be a function of the aeetrizoate concentration. This points to the 
existence of binding sites on the albumin molecule which are not yet 
Ч(/-П ,Λ.' ч_ 
ν- ί 'J ..'V' \-
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occupied in the acetrizoate concentration range studied in the nmr ex­
periments. In view of the data of Lang and Lasser (12) this result was 
somewhat unexpected and therefore a series of equilibrium dialysis ex­
periments were carried out. 
The results of these experiments conducted at 4 С are given in 
Fig. 4, where the average total number of acetrizoate molecules, г , 
bound per albumin molecule has been plotted against the logarithm of 
acetrizoate concentration free in solution. 
1er2 ю-1 
[S] M 
Fig. 4. The average total number of acetrizoate molecules., ν
ψ
, bound 
per albumin molecule plotted as a function of the acetrizoate 
concentration free in solution. The points were obtained from 
equilibrium dialysis experiments conducted at 4 C. The solid 
line is a least square fit to the experimental values based on 
equation 5. 
The points show that in a concentration region around 10 M a first 
binding site is titrated. A second set of sites is titrated at much 
-3 -2 higher concentrations namely from 10 to 10 M and does not show any 
saturation up to the highest concentration studied. On the assumption 
that two different classes of binding sites are present on the albumin 
molecule a curve was fitted to the experimental points (solid line in 
Fig. 4) using equation 5 to describe the binding. To this end a com­
puter fitting procedure was employed based on a gradient method for the 
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nonlinear parameter К and a linear regression method for the linear 
parameter n. The resulting binding parameters together with their 
standard errors are given in table 1 for two series of experiments, 
i.e. at 4° and 30OC. 
Table 1 
Binding parameters for the binding of acetrizoate to BSA 
Class I Class II 
Temperature 
iij. k-j. χ IO"5 M ' n I I У. M ' 
40C 0.85 (.02) 16.0 (.8) 12 (1) 60 (10) 
30oC 0.98 (.02) 4.6 (.2) 9 (1) 120 (20) 
The values in the parentheses are the standard errors 
From Fig. 4 it can be concluded that in the concentration range in 
-3 -2 
which the nmr experiments were conducted (10 - 2 χ 10 M) there 
are at least two types of complexes present in solution. Moreover, in 
this concentration range, the first class of binding sites is satura­
ted, i.e. r = 0.9 throughout the concentration range of acetrizoate, 
explored in the nmr experiments. The values of tg α obtained at 4 and 
30 С are summarized in table'2 together with the experimentally deter­
mined values of г . The chemical shift data have been evaluated in an 
analogous fashion i.e. the slopes of the lines, tg β, obtained by 
plotting 6 versus Ρ
η
/5
η
 (see Fig. 3) were determined for different 
concentrations of acetrizoate and are listed in table 2. 
B. EVALUATION OF THE LINEBROADENING PARAMETERS 
According to eq. 6 
tg α = rjXj + rjjXjj. (16) 
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Table 2 
Linewidth and chemical shift parameters of the acetrizoate-BSA complex 
S0 m M
a ) 
30OC 
1.0 
2.0 
3.5 
6.0 
10.0 
15.0 
20.0 
40C 
1.0 
2.0 
4.0 
6.5 
10.0 
18.4 
- b) 
Τ 
2.0 
2.8 
3.7 
4.7 
6.1 
7.5 
8.7 
1.7 
2.2 
3.1 
4.0 
5.1 
7.0 
linewii 
tg о (ф-Н) 
93 ( 3) 
157 (16) 
207 (18) 
282 (20) 
376 (28) 
-
609 (22) 
85 ( 4) 
179 (10) 
234 (15) 
485 (22) 
565 (II) 
896 (13) 
dth c ) 
tg α 
102 
146 
219 
265 
318 
516 
114 
134 
216 
393 
457 
651 
(сн3) 
( 8) 
(10) 
(15) 
(12) 
(11) 
(30) 
( 9) 
(18) 
(42) 
(25) 
(41) 
(39) 
chemical 
tg В (Ф-н) 
30 ( 3) 
-
103 (10) 
114 (13) 
148 ( 7) 
208 (11) 
253 (22) 
22 ( 3) 
-
31 ( 8) 
60 ( 7) 
95 ( 8) 
126 (22) 
shift c ) 
tg ß (сн3) 
16 ( 5) 
-
43 ( 5) 
62 (15) 
59 (17) 
87 ( 8) 
101 (38) 
10 ( 3) 
-
15 ( 4) 
12 ( 2) 
32 ( 7) 
28 (23) 
a) S
n
 is the total concentration of aaetrizoate 
b) r„ is the total average number of aaetrizoate molecules bound per 
albumin moleoule 
a) The values in the parentheses are standard errors 
The binding experiments (see Fig. 4) have shown that in all rnnr expe­
riments r = 0.9, so that: 
tg α = 0.9 Xj + (rT - 0.9) X I 1 (17) 
Plotting tg α versus (r - 0.9) should yield a straight line with a 
slope given by X and an intercept by 0.9 X . The experimental results 
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obtained at 4 and 30 С are given in Fig. 5 for both the CH_ and the 
ф-Н protons. 
Fig. 5. Plot of tg α versus the average number of aoetrizoate molecu­
les bound to the second class of binding sites, r„ - rT. Each 
point is the slope of a line representing the T« aepenaenae on 
P
n
/S
n3 of which examples are given in Fig. 2. The solid lines 
are Least squares fits based on equation 17. 
A least squares fit to the points results in the values for X T and X--
given in table 3. 
It should be noted in passing that independently of the interpre­
tation of the binding curve (Fig. 4) the nmr data are inconsistent 
with the assumption of one class of binding sites for acetrizoate on 
the albumin molecule. If albumin were to possess only one class of in­
dependent and identical binding sites, the linebroadening parameter 
tg a/r would be concentration independent. 
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Table 3 
Linebroadenïng (X) and chemical shifL· (Δ) 
parameters of the acetrizoate-BSA complex 
class of 
binding sites 
I 
II 
group 
CH3 
ф-Н 
CH3 
ф-Н 
X (sec"1) 
40C 30oC 
27 (20) 
0 (20) 
100 (12) 
141 (14) 
43 (10) 
15 (10) 
59 ( 3) 
72 ( 4) 
Δ (sec 
40C 
0 (10) 
0 ( 5) 
4 ( 2) 
20 ( 3) 
- ) 
30OC 
0 (10) 
0 ( 5) 
12 ( 2) 
32 ( 2) 
Values in thç parenthesee are standard errors 
Examination of Fig. 6, in which tg a/r of the phenylprotons, obtained 
at 30 C, has been plotted as a function of S., clearly reveals a con-
centration dependence, which is compatible only with the existence of 
more than one class of binding sites. 
- 1 — 
θ 
1 — 
10 
1 — 
12 
1 — 
14 
1 — 
16 
1 — 
10 
So 
20 
mM 
Fig. 6. Plot of tg a/r-, versus S. for the ф-Н proton. Temperature 30 C. 
The solid line has been oalculated according to equation 18 
(see text). 
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The line drawn through the points has been calculated using the expres­
sion: 
tg a/rT = 0.9 Xj. + (rT - 0.9) Xjj/r,,, (18) 
The r T values were taken from Fig. 4 and X and X from table 3. 
Except for class I at 4 C, where the standard errors in the line-
broadening parameters are too large, it can be concluded that the values 
of X. for the aromatic and methyl protons are significantly different 
from each other for both classes of binding sites (see table 3). 
Fig. 7. Plot of tg & as a function of the average number of acetrizoate 
molecules bound to the second class of binding sites r_ - г.. 
Each point is the slope of a line representing the 6 dependence 
on PQ/S , of which examples are given in Fig. 3. The solid lines 
are least squares fits based on equation 19. 
С EVALUATION OF THE SHIFT PARAMETERS 
According to equation 8 tg $ is related to the chemical shift parameter 
Δ. as : 
ι 71 
tg В - 0.9 à1 + (rT - 0.9) Δ
Ι Ι 
(19) 
Plotting tg β versus (г - 0.9) should yield a straight line with a 
slope given by Δ and an intercept by 0.9 Δ . The experimental re­
sults obtained at 4 and 30 С are given in Fig. 7 for both the CH. and 
the ф-Н protons. A least square fit to the points results in values 
for Δ and Δ given in table 3. Examination of this data shows that 
the shift parameters Δ of the first class of binding sites are not 
different from zero within experimental error for both the CH. and the 
ф-Н protons. On the other hand the Δ values of the second class of 
binding sites do differ appreciably from zero. Moreover, these values 
decrease significantly with decreasing temperature. 
D. DETERMINATION OF THE DISSOCIATION AND RELAXATION RATES 
As indicated above no chemical shift changes occur upon binding of 
acetrizoate to the specific binding site (class I) of BSA. Consequent­
ly equation 10 will be used to interpret the linebroadening para­
meters. At 30 С the X values of the phenyl and methyl protons are 
significantly different (see table 3). Considering equation 10 this 
inequivalence is indicative of a situation in which only the relaxa­
tion rate, Τ , or both the exchange rate, τ , and the relaxation 
rate, Τ contribute to the value of X . If the lifetime of the al­
bumin acetrizoate complex were much longer than the transversal rela­
xation times Τ of the acetrizoate protons when bound to the albumin, 
the linebroadening parameters X for the ф-Н and CH. protons should be 
equal, contrary to what is observed. 
The lifetime of the acetrizoate - BSA complex of the type I is es­
timated as follows: Firstly from equation 10 and the X values at 30 С 
(table 3) it immediately follows that τ < 0.025 sec. Secondly by making 
a reasonable estimate of the upper limit of Τ (CH.), a lower limit 
of the lifetime of the specific acetrizoate albumin complex can be 
computed. The Τ (CH.) value can be derived from Fig. 1 of a paper of 
Werbelow and Marshall (20). To this end we assume that the acetrizoate 
molecdle is immobilized on the protein surface, wnile the methylgroup 
retains the motional freedom around its axis. Taking the rotational 
_g 
correlation time, τ , of BSA equal to 10 sec (21) and the rotatio-
c 
nal correlation time τ. for the methylgroup rotation around its axis 
-11 i n t -2 
equal to 0.5 χ 10 sec (22) we find Τ (CH ) = 10 sec. This esti­
mate of T. (CH,) is not very dependent on the choice of τ. , but it 
is sensitive to changes in τ . The value of 10 sec chosen for the 
с 
rotational correlation time, τ , of the protein can be considered a 
lower limit since the rotational correlation times of BSA have been 
found to be higher up to one order of magnitude (21). Higher values 
of τ lead to smaller values of T„T (CH,) so that τΤ„ > 0.015 and 
с 21 J IS 
consequently at 30 С 
30 < к < 80 sec" 
where the experimental errors (table 3) have been taken into account. 
It should be noted that within these limits τ is of the same order 
of magnitude as Τ (φ-Η) and smaller than T. (CH ). This is in 
accordance with the temperature dependence of the linebroadening para­
meters X (CH.) and Χ (φ-Η). It is well known that the temperature 
. -1 -1 . . . -1 
coefficients of τ and Τ have opposite signs, i.e. τ has a posi-
2
 -l 
tive temperature coefficient, while Τ has a negative temperature 
coefficient (7). Since X is found to increase with increasing tempe­
rature this indicates the importance of τ in the r.h.s. of equation 
10 in agreement with the findings above. 
The non-specific acetrizoate albumin complex (class II) shows a 
different picture. The X values have negative temperature coeffi­
cients. Moreover, definite changes of the resonance positions, δ, are 
observed upon binding of acetrizoate to albumin. The linebroadening 
parameters X and the chemical shift parameters Δ of both the 
methyl and the phenyl protons and their temperature dependence can be 
described by eqs. 14 and 15 and their temperature derivatives. These 
form a set of eight equations with eight unknowns which can be solved 
using the results in table 3. It turned out that these parameters 
could only be slightly varied within their error limits to give 
73 
physically acceptable solutions for τ
τ τ ς
»
 Т2тт а ш* ώ ωττ ί ο Γ b°th the 
methyl and the phenyl protons. Subsequently the values obtained for 
the latter parameters were substituted in the more general Swift and 
Connick equations 7 and 9 and varied in such a way that the differen­
ces between the calculated and observed values of X and Δ became 
minimal. This resulted in the following lifetimes of the acetrizoate 
albumin complexes (class II): 
at 40C 
at 30OC 
TIIS 
TIIS 
= 
= 
2-2.5 msec 
0.4 - 0.6 msec 
These results imply that there is a relatively large exchange contri­
bution to the linebroadening parameter Χ
τ τ
· However, as would be ex­
pected from the temperature dependence of the linebroadening para­
meters, the Τ parameters do dominate; i.e. at 30 С 
T2II ( Ф" Н ) = l 7 " 2 3 m s e c 
T2II ( C H 3 ) = 1 6 " 1 8 m S e c 
At 4 С these values are about halved. The Δω values are indeed found 
to be of the same order of the Τ values, in accordance with the 
assumptions leading to eqs. 14 and 15 i.e. 
Δω (ф-Н) = 220 rad/sec 
Λω (CH ) = 80 rad/sec 
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DISCUSSION 
A. THE MODE OF BINDING OF ACETRIZOATE AT TYPE II BINDING SITES 
From the results above we find for the spin-spin relaxation rates of 
the methyl and the phenyl protons: 
Т2ІІ (Ó~H) = 5 0 - 10 Sec ' 
T2TT ( C H 3 ) = 59 - 4 Sec~] 
at 30OC 
The spin-spin relaxation time is determined by the correlation time, 
τ , which is characteristic of the tumbling time of the molecule or of 
an individual molecular group, and by the distances between the 
nucleus considered and magnetic moment bearing nuclei in the surroun­
dings. Thus the Τ values of different groups of acetrizoate тэу 
yield information about their mobility with respect to the BSA molecule. 
In the bound state the spin-spin relaxation time of the aromatic 
proton will be determined predominantly by protein nuclei at an un­
known distance. Thus little can be said about the mobility of the 
phenylgroup from T- values alone. However, the ratio of the spin 
lattice relaxation time, T., over the spin-spin relaxation time, T_, 
is only a function of τ and in a temperature and frequency dependent 
study of the binding of sulfonamide to carbonic anhydrase Lanir and 
Navon (23) have shown that these ratios yield reliable τ values. For 
-I c 
this reason spin lattice relaxation rates, Τ , have been determined 
. . -I 
under the same conditions the T« experiments were carried out. For Τ 
a formula analogous to equation 6 can be derived. Τ measurements at 
various BSA and acetrizoate concentrations yielded a value of 
T~' (φ-Η) = 10 sec ' at 30OC. From the ratio Τ /T = 5 we obtain 
τ = 3 χ 10 sec at 30 C. Τ measurements of the methylgroup exhibi­
ted only slight changes with respect to the non-bound situation except 
for the disappearance of the non-exponential behavior (22). As a 
result the Τ (CH ) could not be established with sufficient accu­
racy and the correlation time was directly calculated from the 
-9 T2II ( C lV У і е 1 с і і п8 a value of 3 χ 10 sec. Again Fig. I of the 
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paper of Werbelow and Marshall (20) was used, while assuming that the 
rotation of the methylgroup around its axis is not restricted. The 
results are listed in table 4 together with the values for nonbonded 
acetrizoate and for albumin. Examination of table 4 shows that al­
though the mobility of the phenylgroup of acetrizoate is slowed down 
as a result of binding to the type II binding sites, it still has a 
considerable amount of motional freedom with respect to the BSA mole­
cule. The τ value obtained for the methylgroup is equal to the value 
obtained for the phenylgroup, which indicates that the phenylgroup 
and the methylgroup have about equal mobility on the surface of the 
protein, except for the rotation of the methylgroup around its axis. 
B. THE INFLUENCE OF THE BINDING OF ACETRIZOATE TO ALBUMIN ON THE 
RENAL EXCRETION 
At clinical doses of 200 mg of acetrizoate per kg body weight, plasma 
levels occur up to 1 mM (10). At this concentration about 70% is 
bound to bovine albumin (and probably somewhat less to human albumin 
(12)) of which about three quarters is bound to the first specific 
binding site. Above the dissociation rate of type I complexes was 
found to be in the region 30 * к * 80 sec , which corresponds to a 
lifetime of the albumin acetrizoate complex between 0.03 and 0.012 
sec. This is at least an order of magnitude less than the cortical 
transit time which may vary from .3 to 3 sec (24, 25). Thus in a first 
approximation little influence of the dissociation rate on the active 
tubular excretion of acetrizoate is to be expected. However, such a 
conclusion should be regarded with some care. Although the dissocia­
tion rate is high with respect to the reciprocal transit time, the 
high affinity constant of the acetrizoate albumin complex results in 
a very high association rate constant which might compete with the 
excretion rate. Model calculations (26) show that in the region where 
the albumin complex lifetime equals the transit time the system is 
most sensitive to changes in dissociation rate and that irrespective 
of the dissociation rate, protein binding decreases the amount of ac­
tively excreted drugs as long as the maximum transport capacity has 
not been reached. 
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Table 4 
Correlation times at 30 С 
correlation time 
-1 
Albumin a ) (2 - 20) χ lu"8 
Acetrizoate ^ 3
 χ 10-9 
bound to type II , „ , ^
 |n-9 
binding sites 
φ-Η 3 χ 10 
Acetrizoate
 8 χ ^-12 
free in . „ „ , ,„-10 
solution 
Φ-Η 2.4 χ 10 
a) D. Wallaeh (21) 
b) J.F. Rodrigues de Miranda and C.W. Hilbers (22) 
CONCLUSIONS 
It has been shown, by a combination of nmr and equilibrium dialysis ex­
periments, that the rather complicated binding of acetrizoate to albu­
min can be unraveled. Binding constants for two different classes of 
binding sites have been obtained. 
The lifetime of the specific albumin acetrizoate complex (class I) 
is in the region of 0.012 to 0.03 sec. This value is much less than the 
cortical transit time; further decrease of the lifetime of the complex 
will have little influence on the renal active excretion rate. Compari­
son of the kinetic parameters obtained for the two classes of binding 
sites shows that the difference in the corresponding binding constants 
is mainly caused by the difference in the association rate constants 
i.e. the decrease in the binding constant of 4.6 χ 10 M for type I 
binding sites to 120 M for type II binding sites mainly comes from 
the decrease of к = 2.5 χ 10 sec M to k T = 2 x 1 0 sec M 
rather than from an increase in the dissociation rate constants. Such a 
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phenomenon has been observed earlier for the sulfonamide binding to car-
bonic anhydrase (27). Hence also in the present study the association 
between protein and substrate cannot be described by a diffusion-limi-
ted complex formation. 
The mobility of the acetrizoate molecule when bound to the second 
class of binding sites could be estimated. It turned out that in this 
case the correlation time of the acetrizoate molecule was an order of 
magnitude less than the correlation time of the protein, indicating an 
appreciable amount of motional freedom with respect to the protein. 
The potential possibilities which nmr offers for studying the mo-
lecular dynamics of substrate on protein surfaces has led to a number 
of linebroadening studies of pharmacologically highly interesting sys-
tems. In these investigations linebroadenings have often been inter-
-1 4 -1 
preted to yield values of T» (bound) of the order of 10 sec which 
correspond to linewidths of the substrate resonances of the order of 
3 
10 Hz (28, 29). These values are improbably large, especially when one 
realizes that these linewidths exceed the total spectral width of most 
proteins hitherto observed at 100 MHz. Moreover, the individual reso-
nances of protein residues for instance of hemoglobin are of the order 
of 100 Hz (7) again indicating the unlikely high value of T. (bound) 
obtained in some of these binding studies. It should therefore be stres-
sed that before interpreting linewidth alterations, the exchange limit 
has to be established, moreover, it should be checked whether line-
broadening is a result from binding to only one, or one class, of bin-
ding site(s) in the concentration region studied in the nmr experiments. 
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The renal and hepatic clearance of drugs, which bind to plasma pro­
teins, are concentration dependent, resulting in non-linear kinetics 
of elimination (1). In the kidney the protein bound fraction is not 
susceptible to ultra filtration, whereas with regard to active tubular 
excretion, protein binding may be interfering. Little is known about 
the influence of the dissociation rate of the protein-drug complex on 
the effectiveness of the active transport (2). 
In the present study the dissociation rate of the contrast medium 
acetrizoate (Triognost ) is related to the active tubular excretion 
rate (3, 4). To this end the dissociation rate constant of the acetri-
zoate-albumin complex was deduced from nmr experiments. 
COOH 
I Г^ ||I О Acetrizoate 
Binding of substrate molecules to macromolecules may cause an in­
crease in the linewidths of the nmr signals of the substrate molecules 
(5). If an excess of substrate is used the line broadening is propor­
tional to the fraction, f, , of substrate bound to the macromolecule: 
b 
line broadening = f, . X sec (1) 
The line broadening parameter X is a complicated function of the re­
laxation rate Τ-, , the exchange rate τ and the chemical shift 
zb 
differences between the resonances of the substrate bound to the 
macromolecule and free in solution (6). T-, is the relaxation rate 
2 b
 -1 
of the substrate molecule bound to the protein and τ equals the dis­
sociation rate к of the protein-substrate complex. In absence of 
these chemical shift differences eq. 1 can be simplified to: 
line broadening = f. (τ + Τ0^) (2) 
b zb 
An example of the line broadening observed for the acetrizoate reso­
nances due to binding to albumin is shown in Fig. 1. 
-3 
The lower half of the figure displays the spectrum of a 6 χ 10 M 
acetrizoate solution without albumin. The upperhalf of the figure was 
recorded in the presence of 2.4 χ 10 M albumin. The intense signal 
at about 430 Hz is due to residual HDO. The resonances of interest at 
58, 160, 260 and 780 Hz respectively, recorded on an expanded scale 
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and at higher amplification factor, were inserted in the figure at 
their corresponding frequencies. 
[ 
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Fig. I . nmr> spectra of acetrizoate in D-O-phosphate buffer, pH 7.4. 
Lower spectrum without, upper spectrum with albumin. 
Proceeding from left to right they represent the 0-H of acetrizoate, 
the methylgroups of tetramethylaimoniumchloride, the methylgroup of 
acetrizoate and the methylgroups of t-butylalcohol. The methyl reso­
nances of the tetramethylammoniumchloride and t-butylalcohol were used 
as a check, on the field homogeneity. Addition of albumin clearly shows 
a line broadening of the acetrizoate resonances while the reference 
signals remain virtually unchanged. 
Since the temperature coefficients of Τ and τ in eq. 2 are dif­
ferent in sign, the temperature dependence of the line broadening can 
be employed to establish whether the relaxation rate or the exchange 
rate dominates in the line broadening parameter. The line broadening 
caused by the binding of acetrizoate to the specific binding site on 
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albumin displays a positive temperature coefficient indicative of a 
slow exchange situation. This, together with the inequality of the 
line broadening parameters of the methyl and aromatic protons sets 
the following limits to the dissociation rate constant (7): 
80 > k~ > 30 sec"1 
This dissociation rate constant corresponds to a mean lifetime of the 
acetrizoate-albumin complex of 0.03 - 0.012 sec which is one order of 
magnitude smaller than the mean cortical transit time of 0.3 - 3 sec 
(89). Hence little influence of the dissociation rate on the effecti­
veness of the active excretion is to be expected (2). Such a conclu­
sion should, however, be regarded with some care. To obtain a more 
quantitative view of the influence of protein binding and of the dis­
sociation rate of the drug-protein complex on the active excretion 
rate, differential equations were designed based on simple Michaelis-
Menten kinetics and a non-equilibrium situation for the protein-pharma-
con interaction. By a numerical procedure excretion curves were calcu­
lated; for an example see Fig. 2. Plotted are the relative tubular 
active excretion E/T , with E being the tubular active excretion rate 
m 
and Τ the tubular maximum rate, versus the total concentration of 
m 
substrate in the plasma, C, in mM. The excretion curves have two 
bounderies, indicated by the dashed lines. The horizontal asymptote 
(Ε = Τ ) reflects the capacity limit of the excretion system, the 
m 
sloping one the flow limit of the system (E = V χ С) with V being the 
plasma flow through the system. For the situation indicated i.e. a 
dissociation equilibrium constant, D, of 5.10 M for the albumin-
substrate complex, 5.10 M for the carrier-substrate complex, K, 
-4 
and an albumin concentration. A, of 5.10 M, excretion curves were 
calculated for three different dissociation rates (0 = к /Τ). 
1. No dissociation of the protein-acetrizoate complex occurs: 0 = 0 . 
2. The lifetime of the albumin complex is very much shorter than the 
transit time Τ: β -»• <*> 
3. The lifetime of the complex equals the transit time through the 
pars recta: β = 1. 
For reasons of comparison a fourth curve, (A = 0 ) , representing the 
situation with no protein binding, is also given. From these curves 
it should be noted that even in case the dissociation rate constant 
is very high, 10 sec say, the protein binding still diminishes the 
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effectiveness of the active excretion. 
t -2 -3 -A -5 -6 .7 .8 -9 10 1.1 1.2C(mM) 
Fig. 2. Plot of the active drug excretion as a function of the total· 
drug concentration in the plasma for different dissociation 
rates of the drug-albumin complex. 
V 
A 
60 ml/min; Τ 
S.10-4 M. m 
30 umol/min; К = 5.10 M; D = 5.10 M; 
Symbols are defined in the text. 
In conclusion it can be said that 
i) Irrespective of the dissociation rate, protein binding decreases 
the amount of drug actively excreted as long as the maximum 
transport capacity is not reached. 
ii) In the region where the albumin complex lifetime equals the 
transit time the system is very sensitive to changes in 0. 
More extended calculations will be presented elsewhere. 
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INTRODUCTION 
When the biological activities of stereoisomers (enantiomeric and dia-
stereomeric, such as epimeric or geometric) are compared, it is some-
times found that only one member of each pair is active, often that 
both members are equally active. Very frequently though, both members 
exhibit the same type of activity but to a different degree. Several 
thousand such cases have been recorded (see references 1-79 and other 
literature summarized in 80-85) , most of them for structurally speci-
fic drug action and certain types of enzymatic action. The differences 
in activity for the members of any one pair (most conveniently expres-
sed as the ratio of their activities or potencies) vary enormously, 
viz. from ca. 1 up to nearly 10 . In spite of extended efforts (80-85), 
it has so far not been possible to explain these ratios; every biolo-
gical system, sometimes every individual pair, seems to constitute a 
casus sui generis. 
Actually this failure is partly understandable in view of the 
complexity of receptor-drug and enzyme-substrate interactions (dif-
ferences in intrinsic activity, conformational mobility, simultaneous 
interaction at more than one point, multiple concurrent forms of inter-
action, dualism of action, etc.) and of the experimental difficulties 
which may intervene (faulty estimation of stereoisomeric purity, selec-
tive distribution, accuracy of potency estimates over large spans, 
limited availability of appropriate test cases, enzyme purity, complex 
formation between stereoisomers, etc.). 
Two studies (86, 87) are available, however, in which attention 
is drawn to the fact that the ratio of potencies increases with an in-
crease in the potency of the racemate or of the more potent isomer. 
The seemingly accidental nature of these correlations, as well as the 
lack of a theoretical basis for them, has resulted in their neglect by 
most workers in the fields concerned with this phenomenon. If such cor-
relations are in fact not accidental, their analysis should be useful 
in exploring a fundamental aspect of S.A.R. general to all drug action. 
The present work summarizes the results of a literature search 
aimed at establishing the frequency with which a correlation appears 
either between the potencies of the isomers or directly between the 
ratio of their potencies and the potency of one of them. 
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ANALYSIS OF EUDISMIC-AFFINITY CORRELATIONS 
Discussion of this topic is greatly facilitated by the introduction of 
some new terms defined as follows. In any pair of isomers for which a 
given biological system shows stereoselectivity, the more active one 
will be termed the eutomer (Eu) and the less active one the distomer 
(Dis) regardless of their absolute configuration. A homologous series 
of pairs will then consist of a eutomeric series and a dtstomerta 
series. These are necessary designations because they classify a pair 
on the basis of complex stability. This, which is a consequence of the 
geometry of the active site on the biomacromolecule, is determinant, 
rather than the geometry of the isolated drug which may be irrelevant. 
For any given pair the ratio of their potencies (activities, affini­
ties, efficiencies as substrates, etc.) will be termed the eudismia 
ratio and its logarithm, the eudismia index (E.I.), in analogy to the 
stereoselectivity index used by other authors (e.g. 8). Finally, in a 
homologous series, the rate of change of E.I. for a given increase in 
log potency of the eutomer (log Eu, which usually may be taken as a 
measure of its affinity), will be called the eudisnia-affinity quo­
tient (E.A.Q.). The meaning of these terms should become clear from 
the illustrative example given in Fig. I. Consider a set of three iso­
meric pairs whose relative potencies are as shown in Fig. la. Loga­
rithmic scales are used not only for compactness but also because a 
scale is obtained which is independent of the units employed in the 
potency estimates. 
The use of these terms, derived from ευ = good, όυζ = bad and 
μεροζ = part, is suggested in analogy to the previously proposed 
designations of eutopic (well-fitting) and distopic (ill-fitting) 
complexes (88). 
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After conversion of the potency estimates to logarithmic units, 
any correlation between the eutomerie and distomeric series will be­
come evident in either of two ways. In Fig. lb both have been plotted 
against a common scale. Obviously log Eu against log Eu gives a 
straight line of slope 1 ; but a line dropped from any point on it to 
the point corresponding to the distomer represents the drop in acti­
vity i.e. its E.I. 
Pair 
No 
' 
2 
3 
Isomer 
No 
Eu 1 
Dis 1 
Eu 2 
Dis 2 
Eu 3 
Dis 3 
Re'at.ve 
Potency 
100 
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log· 'elative 
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1 3 5 
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Index ( f i 
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(.à) 
0 1 2 3 Ц а 
loe potency Eu 
( b ) 
Fig. 1. Eudismia-affinity correlation plots, illustrative example. 
a. Table of potencies for a thvee-^pair set. 
b. Separate plots of log Eu and log Dis each vs log Eu; note 
that the vertical distance between any pair of points cor­
responds to the potency drop from Eu to Dis for that pair. 
a. Eudismic-affinity correlation plot. The equation for the 
line shown is E.I. = a + b log Eu, where b = tan 3 - E.A.Q. 
and log Eu = - a/b. These terms are related to the line 
equation for the distomeric series in b. through b' = 1 - b 
and a' = -a for the equation log Dis - a' + b' log Eu. 
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The plot shown in Fig. 1c is an even more compact and convenient 
representation in which the E.I. has been plotted directly against log 
Eu for each pair. The slope of the line obtained then corresponds to 
the change in E.I. per unit change in log Eu, that is the E.A.Q. for 
this system. The intercept of this line with the abscissa will be de-
signated log Eu . 
This type of plot is similar to that used previously by Pfeiffer 
(86) and Ariens and Simonis (87), but differs in that increases in 
potency are plotted to the right, and that all points appear in the 
upper quadrants, which follows from the definition of Eu and Dis. 
From this it may be seen that although the E.I. is always positive, 
the E.A.Q. may be positive, negative or zero. Each case corresponds to 
a different kind of relationship which our data show to exist. 
This type of plot is not only a compact way of summarizing eudis-
mic data, but also displays it in such a way that both visual and 
mathematical analyses of any existing correlations become simple. It 
is used in the examples which follow and is the basis of the data pre-
sented in Tables 1 and 2. 
EXAMPLES OF SOME EUDISMIC-AFFINITY CORRELATIONS 
Before presenting the results of the survey, it is useful to introduce 
the subject by discussing some examples, drawn from the most diverse 
possible fields (pharmacology, enzymology, plant physiology), repre-
sentative of different types of action (chemical reactivity, agonism, 
antagonism, etc.), and of different classes of stereoisomerism (en-
antiomeric, epimeric and geometric). 
In addition, some have been selected because they •show clearly 
certain features of eudismic-affinity correlations which we have found 
to be of general occurrence. 
A figure is given for each example which contains the following 
information: (a) Type of biological activity studied, (b) Structures 
of the stereoisomeric pairs, coded to their position on Lhe plots; an 
asterisk indicates that a given eutomer has an absolute configuration 
opposite to that of the eutomeric series as a whole, and a vertical 
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arrow above a point indicates that only a minimum estimate of the E.I. 
was available. No error estimates are to be inferred from the size of 
the circles about the points, (c) The -lines shown are least-squares' 
estimates through the pertinent points, and the slopes indicated cor­
respond to their E.A.Q. (d) Each eudismic-affinity correlation (E.A.C.) 
is numbered as it appears in Tables 1 and 2, where further data con­
cerning it can be found. 
The activity correlated may be pharmacological activity (pA-, pD., 
dose, relative potency, etc.), or an enzymological parameter (k , 1С,, 
cat M 
К , к ../К,., turnover, etc.). The parameter is taken in such a way that 
J- cat M 
its dimension is M or proportional to it. 
ISOPROPYLPHOSPHOTHIONATES 
The inactivation of cholinesterases by isopropylphosphothionates 
(Fig. 2) involves the alkylation of two different enzymes, presumably 
preceded by the formation of an activated complex: 
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Fig. 2. Inaativation of aholínestevase by isopropylphosphothionates. 
a. Acetylcholinesterase (E.A.C. H 101)· 
b. Butyryloholinesterase (Е.А.СЛ 103) • 
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The following points may be noted: 
1. The nine alkylating phosphothionates vary tremendously in their re­
activity towards each enzyme since a 5-decade span of activity is 
covered. In general both enzymes show a similar reactivity toward any 
given phosphothionate, i.e. circles and squares fall approximately at 
the same point on the log Eu scale. 
2. The acetylcholinesterase (a) displays striking behavior: as the re­
activity of the eutomer increases, the E.I. increases also in a regular 
fashion. The correlation between the two variables is highly signifi­
cant and 91% of the variance is explained by linear regression. The 
slope of the correlation line is an excellent measure of the stereo­
selectivity of this enzyme toward this homologous series of inactiva-
tors. 
3. The butyrylcholinesterase (b) behaves in a completely different 
way: throughout the Α-decade span of reactivity the eutomer is not 
significantly more reactive than the distomer. That is, for it the E.l. 
is constant and not significantly different from zero, and E.A.Q. = 0. 
This indicates (cf. Ariens and Simonis, 87) that the chirality of the 
alkylating agents plays no role whatsoever in the alkylation of this 
particular enzyme. 
DIPHENHYDRAMINE DERIVATIVES 
The second example (Fig. 3) is concerned with the antihistaminic and 
anticholinergic activities of some diphenhydramine derivatives. These 
correlations are typical of a large number of cases encountered for 
pharmacological antagonists. Note that: 
1. Relatively high affinities are involved for both systems. 
2. The eutomeric series follows a different sequence in each system 
for the same homologous series of compounds, indicating that the recep­
tors involved are quite different. 
3. Each set includes one pair in which the eutoroer is of opposite ab­
solute configuration to that of the rest of the series (points with 
asterisks). These can nevertheless be correlated; i.e. affinity, not 
absolute configuration, is of primary importance. With a few exceptions, 
however, such members of a series usually have low affinities. 
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Fig. 3. Activities of diphenhydramine derivatives. 
a. Antihistaminic (E.A.C. H 24J · 
b. Anticholinergic (E.A.C. H I2J • 
MUSCARINIC 1,3-DI0X0LANES 
Some activity correlations of muscarinic 1,3-dioxolanes are shown in 
the next example (Fig. 4). In this figure we examine the interaction 
of one homologous series of substituted dioxolanes with two different 
"receptors": the muscarinic receptor (a and b) and acetylcholinesterase 
(c). 
The lower members of the series {1-6) are agonists which mimic 
AcCh at the muscarinic receptor of guinea-pig ileum smooth muscle. 
The line indicated in (a) was obtained from the four points reported 
in one study (Chang and Triggle 1973, 3). The points whose numbers are 
in parentheses are from a separate study (Belleau and Lavoie 1968, 18) 
and were not included in the correlation but are not out of line. 
Higher homologs (8-10) are antagonists (b) at the same receptor. 
Two important points are apparent from those correlations: 
1. The E.A.Q. is similar for both agonists and antagonists. 
2. The log Eu value is much higher for antagonists than agonists. 
Note that pairs 5 and 6 in (a) and (c), and 9 and 10 in (c) can also 
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be correlated, although two, chiral centers are present. A further 
interesting point is that for agonists the E.I. increases as the size 
of the R'group diminishes. 
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Fig. 4. Activities of muscarinia 1,3-dioxolanes. 
a. Muscarinic agonists (E.A.C. H 4) 
b. Muscarinic antagonists (E.A.C. H 53) 
a. Acetylcholinesterase inhibition (E.A.C. H 135) 
(ABMC is aaetyl-H-methylcholine). 
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ACETYLCHOLINESTERASE 
The work of Belleau and Lavoie on the interaction of three members 
(4-6) as competitive inhibitors of acetylcholinesterase, enables us to 
further extend this comparison. Plot (c) shows us that where in vitro 
affinity constants are compared, a very high correlation is observed. 
Note that the stereoselectivity of acetylcholinesterase is higher than 
that of the muscarinic receptor. 
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BENZOMORPHAN DERIVATIVES 
The excellent correlation obtained in the comparison shown in Fig. 5 
is truly remarkable for the following reasons: 
1. Changes at two chiral centers are involved. 
2. Changes at two different positions are included. 
3. The results are from an -in vivo assay on a whole animal involving 
the antagonism (presumably competitive interaction) of two drugs on 
the analgetic receptor in the CNS. 
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ANTIHISTAMINES 
In contrast to the previous examples, all of which involved true en­
antiomeric pairs resulting from the presente in the molecules of a 
chiral Ρ or С atom, the next example (Fig. 6) involves pairs of 
geometrie isomers (ais/trans) about a double bond, that is, the com­
parison is made between the E and Ζ isomers of a given unsymmetrical 
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olefin instead of between the R and S form of a chiral compound. 
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Fig. 6. Antihistaminie activity of avylvropenca and -butènes. 
(E.A.C, li 6). 
SUBTILISIN 
Although a complex quantity, the ratio k/l·^ is accepted by enzymolo-
gists as a good measure of the "efficiency" of a substrate in typical 
enzymatic reactions. 
The following points are noteworthy in regard to Fig. 7: 
1. Log Eu values range over 3.5 decades and E.I. values over 4 decades. 
2. At least three analogs of the "wrong" absolute configuration show 
high activities, but can be correlated well. 
3. The E.I. for S and 10 are minimum estimates, but judging from the 
overall correlation, should not be too far off (not included in cor-
relation) . 
4. Separate correlations of к (E.A.C. Ч 105) and ІсГ (E.A.C. H 122) 
are also significant, but have different E.A.Q.'s. 
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Fig. 7. Subtilisin-BPN' hydrolysis of N-aaetyl phenylalanine methyl 
ester and structural analogs. 
(0 - phenyl; Nyl = naphthyl; In = indanyl) 
AUXINS 
The availability of no less than 32 pairs of closely related auxin 
analogs (Fig. 8) provides an outstanding test system which strikingly 
confirms earlier observations and allows some new ones. 
1. It is apparent that the points fall into two groups: those clustered 
around line (a) and those about line (b). Each of these corresponds to 
a different structural type: in the first a link is present between the 
aryl moiety and the chiral center, whereas in the second there is none. 
2. The analogs grouped together in set (a) include a large variety of 
different substituents and substitutions. If the criterion for homology 
is made more stringent by considering a subset of analogs in which only 
one substituent is varied, a better correlation may be expected. This 
prediction is strikingly verified by subset (a') (darkened circles) 
which singles out six a-(2-naphthoxy)propionic acids. The coefficient 
of determination for regression to the line indicaLed for this subset 
(E.A.Q. = 1.07) is 0.991. 
3. The correlation shown for the a-arylpropionic acids (b) is inte­
resting in two respects: 
firstly, it shows a negative E.A.Q., that is for it stereoselectivity 
decreases with an increase in affinity. Secondly, the intercept of 
this correlation line on the abscissa is exactly at the point corre­
sponding to an achiral homolog of the series, namely indoleacetic acid, 
the natural plant hormone. 
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In this phase it should be realized that as far as the ratio of 
potency of two isomers is concerned, a slight contamination of the 
eutomer (1 to 2% of the less active isomer) does not influence the 
ratio essentially. 
If the poorly active or inactive isomer (distomer), however, is 
contaminated with 1 to 2% of the eutomer, the ratio (ER) may be drasti 
cally changed. As a rule therefore the ratio found is the lower limit. 
This also makes it understandable that ratios over 200 are exeptio-
nal. A contamination will also contribute to a scatter of the experi-
mental points and implies a downward deviation of the curve at higher 
log Eu values. 
From the above mentioned examples it should now be obvious that 
stereoselectivity does not oeauv randomly but may be correlated with 
log Eu. 
The diversity of circumstances under which correlations are ap-
parent points to the existence of a simple principle, fundamental to 
them. 
SURVEY OF PUBLISHED STEREOSELECTIVITY DATA 
The examples presented have shown that at least for them the eudismic 
index can be correlated with log Eu, although the relation between 
them is not necessarily only an increasing one. To find out if these 
are in some way exceptional cases or whether they are in fact just 
especially obvious cases of a generally occurring relationship, we 
have carried out a survey of published data on this topic covering a 
total of 700 pairs. Although not exhaustive, the data included are 
representative of a variety of systems, isomerism, etc., and include 
a large portion of the more important work undertaken specifically on 
the problem of stereoselectivity. For reasons of saving space only 
the data covering a log Eu span larger than 1 are included in tables 
1 & 2. 
The basic criterion used for inclusion of data was the reporting 
separately of quaniibatioe aotivit;/ estimates for each member of two 
or more isomeric pairs on the same biological or other chiral "recep-
tor" 
DESCRIPTION OF THE TABLES 
The data gathered have been separated into two groups: In group I 
(part of which is given in table 1) are included those sets in which 
an i/n vivo system was employed, such as tissue cultures, isolated or­
gans, whole animals, and microbial colonies, i.e. pharmacological 
systems. In group 2 (part of which is given in table 2) we have placed 
the sets referring to in vitro test systems such as pure enzymes, or 
containing artificial chiral components (silica with chiral "foot­
prints", chiral metal chelate complexes, etc.) corresponding to such 
biomacromolecules. The sets are ranked in order (decreasing) of the 
spans covered by the eutomeric series. 
For each set is given: 
1. A set correlation number (E.A.C. U ). 
2. A concise description of the type of activity involved, the class 
of compounds studied, and the chiral center "epimerized" if more than 
one is present. The type of isomerism involved (0, E or G) is indicated 
between brackets together with the number of pairs included. 
0 - enantiomeric (at carbon or phosphorus) 
E = epimeric (linear or cyclic) 
G = geometric (in the sense of cis/trans) 
Achiral lower homologs (e.g. glycine among amino acids) have not been 
included. 
3. The parameter correlated. 
4. The log Eu span covered. 
5. The E.A.Q. value and the significance of a given correlation. 
Two levels of significance are used: * Ρ < 5.0, + = 5.0 < Ρ < 10.0, 
where Ρ is the probability (in %) that the absolute t-statistic is 
greater than the determined t-value on the assumption that there is 
no correlation. 
For sets with E.A.Q. close to zero (recognizable by the occurrence 
of an entry in the next to last column), the significance of the cor­
relation was established by a direct comparison of log Eu and log Dis 
values, i.e. corresponding to plots such as the one in Fig. lb. 
2 
6. The coefficient of determination r ; when multiplied by 100 it gives 
the percentage of variance explained by the linear regression to the 
calculated least-squares' line. 
7. For those cases with E.A.Q. between -0.3 and +0.3 and a Ρ value of 
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> 10 for the E.A.Q. correlation, is given the average E.I. for such 
series. Its S.D. is included to permit establishing whether it is sig­
nificantly different from zero. 
8. The reference(s) from which the data were obtained. 
ABBREVIATIONS USED IN THE TABLES 
E.A.C. H = eudismic-affinity correlation set number; isom. • isomet; 
0 = enantiomeric (optical); E = epimeric; G « geometric; E.A.Q. » eudis-
mic-affinity quotient; Ave. E.I. (S.D.) = average eudismic index and 
standard deviation for sets with E.A.Q. not significantly different 
from zero; Ref. = reference. 
A.a. = amino acid; AcCh = acetylcholine; act. » activity; alt. = al­
tered; antichol. = anticholinergic; D = dose; e.p. = electro shock 
protection; est. = esterase; g.p.i. = guinea pig ileum; hydrol. = hydro­
lysis; inact. = inactivation; inh. = inhibition; k, = dissociation 
α 
constant; Ir = logarithm of the rate; ρ = negative logarithm; 
parasymp. = parasympathomimetic; r.b.c. = red blood corpuscle; 
r. = renal; rel. = relative; r.i. = rat intestine; r.p. = relative po­
tency; synth. = synthetase. 
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Table 1 
Eudismic affinity correlations 
E.A.C. Description of activity, drug series and system correlated 
H 
1 Parasymp. of acyl-altered cholines (g.p.i.) [o,E;10] 
2 Muscarinic of acyl cholines (g.p.i.) [θ;4] 
3 Parasymp. of acyl cholines (g.p.i.) [E;9] 
4 Muscarinic of N -dioxolane agonists (g.p.i.) [θ;4] 
5 a-Sympathomimetic of phenethylamines (r.i.) [θ;4] 
6 Antihistaminic of arylpropenes and -butènes [G;8] 
7 Meperidine-analgesia antagonism by benzomorphans [0;5j 
8 Inh. of flax-root growth by aryloxycarboxylic acids [θ;26] 
9 Anticholinergic of hyoscyamine derivatives (g.p.i.) [0;5] 
10 Glucose-lowering of sulfonamides [θ;8] 
11 Inh. of flax-root growth by arylpropionic acids [θ;6] 
12 Anticholinergic of diphenhydramine derivatives [0;6] 
13 Bronchodilatory of adrenaline analogs (g.p. lung) [0;3] 
14 Antihistaminic of diphenhydramine derivatives [0;b\ 
15 Melanophoretic of [ij-altered a-MSH pentapeptides [E;5] 
16 Tropines for post-ganglionic AcCh receptors [0;4] 
17 Analgetic of piperidines rel. to morphine [E;3] 
18 Anticholinergic of various bases (g.p.i.) [0,E;6] 
19 Antihistaminic of diphenhydramine analogs [Ъ;3] 
20 Muscarinic of N -dioxolanes [p;4] 
21 Anticholinergic of diphenhydramine analogs [0;3] 
22 Glucose lowering of sulfonamides [0;8] 
23 Myotrophic of angiotensin heptapeptides [E;I0] 
24 Uterotonic of [β]-altered vasopressins [E;3 
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for pharmacological systems 
par. 
cor. 
PD2 
PKd 
PD2 
PD2 
PD2 
PA2 
PED50 
PCI50 
PA2 
pD 
PC, 
PA, 
pr.p. 
PA2 
pr.p. 
PKd 
pr.p. 
PA2 
PA2 
pr.p. 
PA2 
pD 
pr.p. 
pr.p. 
Log Eu 
span 
6.70 
5.21 
4.90 
4.22 
3.70 
2.84 
2.79 
3.00 
2.58 
2.48 
2.48 
2.51 
2.43 
2.40 
2.36 
2.14 
1.93 
1.86 
1 .86 
1.85 
I .81 
1 .00 
1 .04 
1.71 
E.A.Q. 
0.30* 
0.27+ 
0.03* 
0.39+ 
0.59 
0.72* 
0.85* 
0.86* 
0.42+ 
0.96+ 
-0.37+ 
0.76* 
0.32 
0.52* 
0.14* 
0.05 
0.71 
0.14 
0.93 
0.57 
0.63 
0.63 
-0.24* 
0.69 
r' 
0.56 
0.88 
0.98 
0.98 
0.62 
0.63 
0.93 
0.77 
0.77 
0.55 
0.65 
0.84 
0.37 
0.70 
0.93 
0.01 
0.60 
0.10 
0.91 
0.14 
0.69 
0.10 
0.82 
0.31 
Ave. 
E.I. (S.D.) 
1.1(.9) 
0.4(.3) 
0.7(.3) 
0.3(.2) 
Ref. 
I 
2 
1 
3 
4 
5 
6 
7 ab 
8 
9 
7 ab 
11 
12 
11 
13 
14 
15 
16 
17 
18 
17 
10 
19 
20 
Table 1, continued 
E.A.C. Description of activity, drug series and system correlated 
H 
25 LRF-like of [б]-altered LRF decapeptides in vitro [Е;3] 
26 Antichol. α-methyltropinoyl cholines (g.p.i.) [θ;]2] 
27 Anticholinergic of hyoscine derivatives (g.p.i.) [p;¿i] 
28 Hexobarbital potentiation by tropinic phenothiazines (j¡;3] 
29 Analgetic of piperidinol esters rel. to morphine [EIST] 
30 Inh. of oat coleoptile-growth by carboxylic acids [0;7] 
31 Inh. of wheat-root growth by carboxylic acids [0;3] 
32 Anticholinergic of glycolyl cholines (g.p.i.) [θ;12] 
33 Antidiuretic of [β]-altered vasopressins [E;?] 
34 Rat pressor of [2]-altered angiotensin heptapeptides [E;])] 
35 Analgetic of diapromide derivatives [0;3] 
36 Melanophoretic of [4]-altered a-MSH pentapeptides [Е;4] 
37 Anticholinergic of acetylcholines (g.p.i.) [θ;12] 
38 Arterial contraction by phenylisopropylamines [0;3] 
39 Anticonvulsant of glutarimides (e.p.) [Ò;5] 
40 Stim. of wheat-root growth by carboxylic acids [θ;5] 
In order to save space the E.A.C.'s 40 - 57 with more than two pairs 
in their sets (Ref. 37 - 49) are excluded from this table; they are 
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par. Log Eu 
cor. span 
pr.p. 
PA2 
PA2 
PED50 
pr.p. 
pCI20 
PCI50 
PA2 
pr.p. 
pr.p. 
PAD50 
pr.p. 
PA2 
P E D 3 O 
PED50 
PCS20 
1 .68 
1.50 
1.43 
1.41 
1.33 
I .20 
2.20 
1 .18 
1.17 
1 .05 
1.05 
1.04 
1 .04 
1.00 
1 .00 
1 .00 
in their sets (Ref. 27 
however included in ta 
E.A.Q. 
0.52 
-0.08* 
-0.13+ 
0.43* 
0.27* 
-0.07* 
0.80 
0.21 
0.14 
0.25* 
0.46 
0.68 
0.13* 
0.06 
0.09* 
0.86 
0.09 
0.72 
0.88 
0.99 
0.83 
0.64 
0.77 
0.11 
0.01 
0.55 
0.77 
0.49 
0.73 
0.95 
0.93 
0.59 
- 36) and the E.A.C.'s 
ile 3. 
Ave. Ref. 
E.I. (S.D.) 
21 
1.9(.3) 8 
l.5(.3) 8 
22 
0.5(.2) 23 
0.6(.3) 7b 
7b 
8 
20 
0.7(.4) 19 
24 
13 
0.3(.2) 8 
25 
0.2(.l) 26 
7b 
58 - 88 with two pairs 
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Table 2 
Eudismic-affinity correlations 
E.A.C. Description of activity, enzyme and substrate series 
101 Inact. of r.b.c. AcCh-est. by iPr-phosphothionates [0;9j 
102 α-СТ hydrol. of methyl esters [θ;14] 
103 Inact. of butyrylcholinester. by iPr-phosphothionates [0;9j 
104 Inact. of beet-brain AcCh-est. by iPr-phosphothionates [Ь;б] 
105 Subtilisin BPN' hydrol. of methyl esters [θ;12] 
106 Carboxypeptidase hydrol of L-Phe amides [Е;3] 
107 α-СТ hydrol. of Z-a.a. PNP esters [θ;7] 
108 Carboxypeptidase-A hydrol. of [3]-alt. Ala-peptides [E;8] 
109 α-СТ hydrol. of N-acylalanine methyl esters [θ;1θ] 
110 Inact. of aliesterase by iPr-phosphothionates [0;6j 
111 Inact. of r.b.c. AcCh-est. by PNP phosphothionates [0;5j 
112 Inh. of AcCh-est. by piperidinium salts [E;A[] 
113 Renal acylase-I hydrol. of a-chloropropionyl amides [E;4] 
114 α-СТ hydrol. of methyl esters [θ;14] 
115 L-A.a.-oxidase act. (Naja flava) on ß-alt. a.a. [E>3] 
116 R. acylase-I hydrol. of [2]-alt. alanyl dipeptides [E;4] 
117 Inact. of α-СТ by PNP phosphothionates [θ;5] 
118 Hydrol. of [l]-altered glycine dipeptides [θ;16] 
119 Glutamine-synth. catalyzed reaction of glutamates [θ,Ε;5] 
120 Carboxypeptidase-A hydrol. of [3]-alt. Ala peptides ^E;8] 
121 α-СТ hydrol. of acylalanine methyl esters [b;8] 
122 Subtilisin BPN' hydrol. of methyl esters [θ;12] 
123 Inact. of butyrylcholinest. by PNP phosphothionates [0;5] 
124 Lipolytic -in vitro act. of adrenergic amines L0;4] 
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for enzymological systems 
par. 
cor. 
Ir 
Ik 
с 
Ir 
Ir 
Ik 
с 
IV 
о 
ik3 
Р^ 
Ik 
о 
Ir 
Ir 
PK, 
IV 
о 
*н 
IV 
о 
IV 
о 
Ir 
IV 
о 
IV 
m 
Ik 
IK 
о 
р ^ 
Ir 
PD, 
Log Eu 
span 
4.87 
4.35 
4.18 
3.59 
3.18 
3.18 
2.52 
2.58 
2.50 
2.29 
2.27 
1.87 
1.73 
1.73 
1.60 
1.60 
1.58 
1.56 
1.52 
0.74 
1.45 
1.60 
1.40 
1.30 
E.A.C. 
0.62* 
0.60* 
0.06* 
0.67* 
1.33* 
0.72 
0.62* 
0.32+ 
0.68 
-0.22* 
0.67* 
0.06* 
0.49+ 
0.20+ 
0.87 
-0.06* 
-0.04* 
-0.13* 
0.36 
0.68 
-0.10* 
0.38* 
0.11* 
0.94+ 
r
2 
0.91 
0.34 
0.97 
0.92 
0.64 
0.87 
0.64 
0.45 
0.25 
0.97 
0.96 
0.95 
0.90 
0.39 
0.87 
0.99 
0.82 
0.86 
0.13 
0.18 
0.77 
0.43 
0.92 
0.89 
Ave. 
E.I. (S.D.) 
0.5(.3) 
0.4(.3) 
0.3(.2) 
0.4(.4) 
2.6(.l) 
0.7(.3) 
0.3(.2) 
0.3(.3) 
0.2(.2) 
Ref. 
51 
52 
51 
51 
52bc 
53 
54 
55 
56 
51 
57 
58 
53 
52 
59 
53 
60 
61 
62 
55 
56 
52bc 
60 
63 
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Table 2, continued 
E.A.C. Description of activity, enzyme and substrate series 
125 Inact. of acetylesterase by PNP phosphothionates [0;5] 
126 α-СТ hydrol. of а.a. PNP esters [o;3] 
127 α-СТ hydrol. of Z-a.a. PNP esters [θ;?] 
128 Inh. of Cholinesterase by piperidinium salts [E;4] 
129 Carboxypeptidase-A hydrol. of [4] -altered Ala peptides [Eis] 
130 Renal acylase-Ia hydrol. of acetyl а.а. [Ъ;7] 
In order to save space the E.A.C.'s 131 - 144 with more than two pairs 
in their sets (Ref. 72 - 79) are excluded from this table; they are 
RESULTS OF THE SURVEY 
In table 3 is given a synopsis of all data treated. The following 
conclusions may be drawn: 
1. Significant correlations were found for 59 of the 101 sets (n ^ 3) 
examined. These included 69% of the total of 700 pairs. 
2. In these, E.A.Q.'s greater than zero were as common as values near 
zero. Negative values occur rarely. Of the sets with zero slopes only 
1/3 differed significantly from zero E.I. 
3. The non-significant three-point sets together with the two-point 
sets as a whole reflect a similar distribution, namely a preponderance 
of positive E.A.Q.'s, frequent occurrence of zero E.A.Q. and infre­
quently negative values. 
As might have been expected, tables 1 and 2 show that significant 
correlations are found mainly when a large log Eu span is covered. 
This is in fact perfectly understandable when all the complexities 
involved are kept in mind. Conversely therefore, it should not be 
surprising that no significant correlation is seen when this condition 
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par. 
cor. 
Ir 
ik3 
PSI 
PK, 
Ík 
Ir 
Log Eu 
span 
1.37 
1 .37 
1.34 
1.28 
1.15 
1.01 
E.A.Q. 
1.00* 
1.53* 
-0.10* 
-0.22 
0.15 
-0.64* 
2 
r 
0.86 
0.99 
0.71 
0.98 
0.52 
0.60 
Ave. 
E.I. (S.D.) 
0.3(.3) 
0.5(.2) 
3.4(.5) 
Ref. 
60 
64 
54 
58 
55 
65 
in their sets (Ref. 66 - 72) and the E.A.C.'s 145 - 161 with two pairs 
however included in table 3. 
is not fulfilled. This is clearly borne out by the data which show 
that most of the sets covering small log Eu spans (e.g. 1.00 or less) 
show no correlation. 
Ill 
Table 3 Synopsis of Tables 1 and 2. 
Numbers of 
in set = η 
η ^ 3 
η = 2 
pairs 
< 
• 
^ 
y 
\ 
Significance E.A.Q. Ave. 
E.I. 
Significant 
< 
¿ 0.3 
í -0.3 
-0.3-0.3 Ζ"' 0 
Subtotal 
Non-signi­
ficant
 < 
^ 0.3 
Í-0.3 
-0.3-0.3 
Subtotal 
Totals for sets with η = 3 
£ 0.3 
$-0.3 
-0.3-0.3 
Totals for sets with η = 2 
Totals for all sets 
Number of sets 
group 1 
12 
2 
10 
4 
28 
21 
1 
7 
29 
57 
13 
6 
12 
зТ 
88 
group 2 
15 
1 
10 
5 
зГ 
11 
1 
1 
13 
44 
6 
3 
8 
ТУ 
61 
Total (%) 
27 (26.5) 
.3 ( 3.0) 
20 (19.8) 
9 ( 8.9) 
59 (58.4) 
32 (31 .7) 
2 ( 2.0) 
8 ( 7.9) 
42 (41.6) 
101 (100) 
19 
9 
20 
48 
149 
Number of sets 
group 1 
85 
12 
77 
30 
204 
86 
5 
43 
134 
338 
26 
12 
24 
62 
400 
group 2 
100 
7 
79 
22 
208 
49 
3 
3 
55 
263 
12 
6 
16 
34 
297 
Total (%) 
185 (30.8) 
19 ( 3.2) 
156 (26.0) 
52 ( 8.6) 
412 (68.6) 
135 (22.5) 
8 ( 1.3) 
46 ( 7.7) 
189 (31.4) 
601 (100) 
38 
18 
40 
96 
697 
POOLED DATA 
MEAN STEREOSELECTIVITY 
The 700 pairs were also examined to see if any general trends are evi­
dent. A plot on a common affinity scale is obviously impossible, but 
all sets have in common a point on the E.I. scale, namely that at 
which E.I. is zero. The corresponding log Eu value can be calculated 
from the equation 
E.I. = a + (E.A.Q.) (log Eu) 
to be log Eu
o
 = - j ^ -
where a is the intercept of the line on the E.I. scale (see Fig. 1c). 
By translating all the points sideways on the log Eu scale by an 
amount equal to log Eu , they can all be plotted together. Such a plot 
in effect asks what is the average increase in the E.I. for a given 
increase in affinity. Fig. 9 is a plot of some 200 points belonging 
to the 30 sets of the total of 101 sets which show a significant cor­
relation to lines of non-zero slopes i.e. with E.A.Q. φ 0 . 
The best line through all the points is 
E.I. = 0.56 + 0.09 + 0.42 + 0.03 log Eu 
η = 199, г 2 = 0.434, Ρ < 0.1%. 
The mean E.A.Q. is significantly different from 1, the value 
predicted by the Easson-Stedman model (see Part 2). 
The points of the non-significant correlations or those of E.A.Q. 
about zero could not be included because the uncertainty of their cal­
culated intercepts is so great that inclusion is meaningless and would 
be misleading. 
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Fig. 9. Pooled plot of all nets with significant correlation and 
E.A.Q. significantly different from zero. 
E.I. - 0.56 + 0.09 + 0.42 + 0.03 log Eu; η - 1Э9; г2 = 0.434: 
Ρ < 0.1%. 
AGONISTS AND ANTAGONISTS 
Group 1 includes many sets that do have a well-defined scale, namely 
the pharmacological studies in which pD or pA. values are given. For 
competitive antagonists the pA values represent true affinity con­
stants. The same holds true for the pD value of partial pharmacologi­
cal agonists. In case of receptor reserve (which implies that only a 
fraction of the receptors has to be occupied to obtain a maximal re­
sponse) the pD 2 values will not represent affinity constants directly. 
Fig. 10a shows a common plot for 41 points of 9 sets of agonists and 
Fig. 10b for 102 points of 18 sets of antagonists. Points belonging 
to non-significant correlations and two-point sets are included. 
It can be seen that although similar, the E.A.Q. for agonists is 
somewhat lower than that for antagonists, although not significantly 
so (P = 16%). More important though is the difference of the inter­
cepts of the lines (log Eu ): for agonists at a pD value of 2.44 and 
for antagonists at a pA value of 5.15 (P about 5Z that they are e-
qual). 
From this it can be concluded that (a) the E.A.Q. of a receptor 
in general is somewhat higher for antagonists and (b) that the same 
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E.I. is achieved only at much higher (about 630 fold) affinities for 
antagonists than for agonists. This confirms the generality of the 
same observations made on one system (Fig. 4, plots a and b). 
EI 
40 
30 -
20 
10 
00 
(a) agonists 
1 г 
00 20 
logEu0-.2 4 
— \ 1 1 Г-
40 60 
—ι 1 1 1 r— 
8 0 100 120 
log Eu (pD2) 
M0 
30-
20 
10 
00 
(b) antaComsfcs 
0 0 
Fig . 10. Pooled plots of vhawaoologi^ol systems on their common 
log Fu scales. 
a. pD„ values of agonists 
E.I. = -О.вО +_ 0.41 + 0.25 +_ 0.06 log Eu; log Eu - 2.44 
η - 41; г2 - О.гОЬ; I < 0.1%. ' о 
b. рЛ„ values of antagonists 
E. Г. = -1.89 + О.ЬО + 0.37 + 0.06 log Eu; log Eu - 5.25; 
η = 102; г2 = 0.275; Ρ < 0.1%. ' 0 
GLOBAL STEREOSELECTIVITY 
In Fig. 11 is shown a pooled plot of nearly 700 points belonging to 
all the sets in groups 1 and 2. It confirms the generality and vali­
dity of eudismic-affinity correlations. 
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Fig. il. Pooled plot of all points. 
After translation to a common origin (as in Fig. 9), the 150 
sets, comprising a total of 700 points, were plotted together. 
The figure shows its central portion and includes some 90% of 
these points. Note the definite skewness of the distribution. 
(No special significance should be attached to the points 
falling far off center; their position is an artifact due to 
the uncertainty of the calculated intercepts). 
EUDISMIC-AFFINITY CORRELATIONS AS A GENERAL PHENOMENON 
Especially noteworthy is the fact that the correlations are not re-
stricted to chiral pairs, but are also found for prochiral molecules 
such as geometric isomers. In fact they have also been detected in 
drug groups where the eutomeric and distomeric series are not isomeric 
but homologous; for example for eudismic pairs of tertiary and quater-
ne 
nary (methyl) ammonium derivatives (87), and for eudismic pairs of 
antihistamines with phenyl and para-chlorophenyl moieties (89) . 
CONCLUSIONS 
We can summarize the salient features of eudismic-affinity correla-
tions as follows: 
1. They are observed for very diverse systems, indicating a general 
occurrence ; 
2. The quality of a correlation improves 
a. as the span covered by the log Eu values increases 
b. when relative affinity and not absolute configuration are con-
sidered; 
3. Eudismic-affinity quotients are 
a. usually positive but may also be zero, and occasionally negative 
b. when positive, they are usually less than one 
c. may be different for different receptors interacting with the 
same homologous series 
d. may be different for different homologous series at the same re-
ceptor; 
4. Achiral lower homologs may also be correlated although not always; 
5. For the same receptor agonists and antagonists have similar 
E.A.Q.'s but a given E.I. is achieved only at much higher affinities 
for the antagonists (higher log Eu values). 
In conclusion then, on the basis of these data, it would seem 
that: 
1. Stereoselectivity does not occur randomly but is often correlated 
to activity, respectively, affinity; 
2. Most often stereoselectivity increases with affinity, but not al-
ways; it often remains constant and occasionally decreases; 
3. Correlations occur widely and may be expected under given circum-
stances in the interaction of chiral or prochiral small molecules with 
geometrically defined sites (active sites, receptors) on biomacromole-
cules. 
4. The general occurrence of this phenomenon certainly warrants 
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further investigation along the lines indicated and an analysis of the 
underlying principle. An interpretation of the observed correlations 
on the basis of a thermodynamic analysis of a generalized Easson-Sted-
man model for such interactions will be presented in Part II. 
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INTRODUCTION 
Shortly after his resolution of the enantiomeric tartaric acids, 
Pasteur (!) observed that only one of them was metabolized by a mold. 
Some years later Piutti (2) reported that L-asparagine was tasteless 
in contrast to the naturally occurring D-asparagine which has a dis-
tinct sweet taste. This was another confirmation of Pasteur's (3) 
brilliant deduction that such phenomena must involve diastereomeric 
interactions between the enantiomers and a disymmetric receptor site. 
Numberless further examples of stereospecific phenomena have been 
found subsequently. This led to the generally accepted view that 
stereospecificity is a characteristic of life processes. 
From pharmacological studies, however, a different picture emerged: 
in many enantiomeric pairs both isomers were found to have definite, 
but different, potencies (cf. Beckett's review, 4). Occasionally also, 
enzymes were found to exhibit such stereoselectivity (Ammon, 5) 
A considerable step forward in our comprehension of these obser-
vations was made possible with the model introduced by Easson and 
Stedman (6) to explain the relative potencies of enantiomers. They 
postulated that the receptor resembles a surface (rather than a cleft) 
in which three points disymmetrically and rigidly disposed interact 
with chiral agents. If one isomer has three groups interacting with 
three points on the receptor site then its enantiomer can only inter-
act with a maximum of two of these. They adduced impressive evidence 
in favor of this model by showing that 1) removal of one of the three 
groups led to an achiral analog whose activity was similar to that of 
the weaker isomer, and 2) that replicating one of the interacting 
groups to produce another, also achiral, analog re-established activity 
as expected. A further evaluation of the three-points-interaction model 
was performed by Niemann et al. (7), who considered the possibility of 
"wrong-way binding", i.e. alternate binding modes, and attempted to 
determine "microscopic association factors" for each interaction of 
every possible binding mode in the particular case of chymotiyptic 
action. 
The observations of stereoselectivity cited above, refer to the 
interaction of more or less closely related series of substrates or 
drugs with their enzyme or pharmacological receptor. The remarkable 
observation of Pfeiffer (8) called attention to the wide occurrence of 
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stereoselectivity. For 14 different drugs he found an excellent cor-
relation between the enantiomeric potency ratio and potency (average 
human therapeutic dose). This and the observations by Ariens et al. 
(9) suggest that we are dealing with quite a general phenomenon (10). 
To check whether this can be confirmed, the literature has been syste-
matically searched for biological activities of stereoisomers. The 
results have been given in the preceding paper (11). It presents a 
survey of available data on the biological activities and enzymological 
susceptibilities of stereoisomers, and shows that stereoselectivity 
does not occur randomly but is, in general, a function of the potency 
or affinity of the more potent isomer. 
In this second part an attempt is made to trace the general prin-
ciple which seems to be underlying the observed correlations between 
the enantiomeric potency ratio and potency. On the basis of the con-
cepts introduced by Easson and Stedman (6) and Niemann et al. (7), a 
binding model will be developed which rationalizes those eudismic cor-
relations in which the affinity constant can be considered as a measure 
of the potency. Special attention will be paid to the different slopes 
(obtained by plotting the enantiomeric potency ratio versus the poten-
cy) , encountered in part 1. 
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DIASTEREOMERIC PHARMACON-RECEPTOR INTERACTIONS 
The usual description of the pharmacon-receptor interaction: 
k, 
[F] + [R]
 r
-
!
^ [RF] •effect (1) 
k
-i 
[RF] = К [R] [ F ] where К = k /k_ (2) 
does not offer a basis for dealing with eudismic interactions. In order 
to do this it is necessary to consider explicitly individual group con­
tributions to the overall affinity constant К (cf. the "microscopic 
binding factors" of Niemann et al., 7). 
The stereoselectivity of biological activity observed for stereo­
isomers must be based on diastereomeric interactions between chiral or 
prochiral molecules and a disymmetric site on the macromolecular recep­
tor molecule or enzyme. Such interactions necessarily imply that the 
macromolecule has three or more points of attachment for which select 
types of molecules show high affinity. These points may lie in a plane 
or not (e.g. the cleft in lysozyme) and may be symmetrically disposed, 
or not, about a point which can be designated as the chiral center of 
the FR-complex. 
We will discuss the subject by dealing with the most general case 
of a four-point chiral arrangement symmetrically (tetrahedral) disposed 
in space. To facilitate the discussion the following definitions intro­
duced in part 1 will be used: 
In a homologous series of stereoisomeric pairs (enantiomeric or dia­
stereomeric, such as geometric or epimeric) the stronger and weaker of 
each pair are designated eutorier (F.u) and distomer (Dis) respectively, 
independently of their absolute configuration. 
Since the description given below is limited to those cases in 
which the affinity constant, K, can be considered as a measure of the 
potency, log (potency) of the eutomer is designated as log К (contra-
Eu 
ry to part 1, in which it was designated as log Eu). The ratio of the 
potencies of the isomers is defined as the eudismic ratio (E.R.). while 
its logarithm is defined as the eudismio index (E.I.). Finally, the 
change of E.I. per unit change in log К is termed the eudionir-affi-
CiU 
nity quotient (E.A.Q.); it is a quantitative estimate of stereoselectivity. 
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SPATIAL ASPECTS 
Consider a rigid receptor with four sites (A, B, C, D) so disposed 
spatially as to interact optimally with one enantiomer of a tetrahedral 
molecule bearing four groups (a, b, a, d) about a chiral atom such as 
С or P. Keeping one group fixed (for example d on D in Fig. 1), it can 
be seen that three different arrangements are possible for each enan­
tiomer. Since any of the four groups could be fixed at D, there are a 
total of twelve arrangements possible for each enantiomer. These can be 
described in terms of the individual contacts; for example one is 
Aa Bb Cc Dd. 
¿A cB bC dP cA bB aCdD 
ЬА ¿>B cC dD 
Fig. 1. Possible arran'jemcnLs of the R (above) and S (below) forms 
of a chiral agent with a tetrahedral receptor of ohirality 
complementary to the R-form. When one interaction is fixed 
(d on D) there are three possible arrangements for each en-
antiomer. Congruences are underlined. 
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All 24 arrangements are conveniently handled in terms of the permuta­
tions of an 4 χ 4 matrix (7). The 12 permutations with an even number 
of inversions defining them as positive correspond to the eutomer ar­
rangements and the 12 permutations with an odd number of inversions 
(negative signs) to those of the distomer (see table 1). 
Designating contacts between site and group bearing the same 
letter as congruences, it can be seen that the eutomer evinces one qua­
druple and 8 single congruences, whereas the distomer has only 6 double 
congruences. Note that three-point contacts, i.e. tridentate complexes 
do not exist for the eutomer; likewise for the distomer monodentate 
complexes are absent. 
BINDING ASPECTS 
Let us consider a stepwise formation of the tetradentate complex via 
mono-, bi- en tridentate intermediates: 
A a 
R¿B + b F^ \ ^ ^ R_ A a_ F/ b c 4 . C^ Aa с 
\;C с ^ ^ s \ ^ D- ^ВЬ^ --d 
D d / D d 
k„ Aa. k„ 
A. «> 
Ja, .-,ф
м
 Jut .¿J*, 
Dd 
then the concentration of each complex can be written (in simplified 
notation) as: 
&-FJ = kAa И M (4) 
[R = F] = k A a k B b [R] [F] (5) 
[REF] = k A a k B b k C c [R] [F] (6) 
[ R = F ] = k A a k B b k C c k D d [R] [F] (7) 
where К . are group-affinity constants for the individual steps. Below 
they will be replaced by k.. The designations к , к , к , к do not 
refer to particular substituents but to a ranking which is chosen as 
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Table 1 
Tetrahedral diastereomeric arrangements 
Aa 
Ab 
Ac 
Ad 
Ba 
Bb 
Bc 
Bd 
Ca 
Cb 
Cc 
Cd 
Da 
Db 
De 
Dd 
Factorization Positive Negative 
Aa 
Bb Cb Db 
Bc Cc De 
Bd Cd Dd 
Aa Bb Cc Dd 
Aa Bd Cb De 
Aa Bc Cd Db 
Aa Bd Cc Pb 
Aa Bb Cd De 
Aa Bc Cb Dd 
I Ba Ca Da 
Ab , Bc Cc De 
I Bd Cd Dd 
Ab Ba Cd De 
Ab Bd Cc Da 
Ab Bc Ca Dd 
Ab Ba Cc Dd 
Ab Bd Ca De 
Ab Bc Cd Da 
Ac 
Ba Ca Da 
Bb Cb Db 
Bd Cd Dd 
Ac Ba Cb Dd 
Ac Bd Ca Db 
Ac Bb Cd Da 
Ac Bd Cb Da 
Ac Ba Cd Db 
Ac Bb Ca Dd 
Ad 
Ba Ca Da | 
Bb Cb Db ι 
Bc Cc De 
Congruences 
Ad Bc Cb Da 
Ad Ba Cc Db 
Ad Bb Ca De 
1 quadruple 
and 8 single 
Ad Ba Cb De 
Ad Bc Ca Db 
Ad Bb Cc Da 
6 double 
к > к, > к > k j . 
а о с d 
In view of the high affinities normally encountered for pharmaco­
logical receptors (pA- or pD. "v 6-9) we can safely infer that only 
multidentate complexes are important, i.e. we can neglect the contri­
butions from single congruences. In this event, as follows from the 
previous section, only tetradentate complexes for the eutomer and bi-
dentate complexes for the distomer need be considered. Thus we can 
immediately write down the concentrations of the effective complexes 
(table 1) of both enantiomers: 
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Eu : [ R = F ] = ^ [R] [F] =
 k a k b k c k d [R] [F] (8) 
and 
D i s : [R=F] = K J J ^ [R] [F] 
=
 ( k
a 4 + k a k c + k a k d + 4 k c + k b k d + W M M 
(9) 
EUDISMIC ASPECTS 
If the pharmacological response is directly proportional to the concen­
tration of effective FR-complexes (neglecting intrinsic activity), the 
potency ratio, E.R., equals the ratio of the effective complex concen­
trations and by taking the ratio of (8) over (9). 
E.R. 
[RMF] 
LR = Fj 
ie к kL к к 
a b c d
 (10) 
1С . к к, + к к + к к . + к, к + к, к , + к к., 
Ois a b а с a d b c b d c d 
It can be seen that eutomer potency is a fourth-order term whereas 
distomer potency is the sum of six second-order terms. Thus both are 
increasing functions of k., but 1С, will increase much faster than 
1С. . It can easily be shown that, if - within a series of compounds -
an increase of one group-affinity constant is not associated with a 
decrease of another, E.I. is a positive increasing function of log К . 
Eu 
EUDISMIC RELATIONS 
All observed eudismic relations (Part 1) are contained implicitly in 
eq. 10. Because of its complex nature certain resonable simplifying 
assumptions will be made. These allow the derivation of simple explicit 
expressions for E.A.Q. which can be used to test the above model 
against the experimental data of Part 1 . 
Our main assumption is that к >> к . Then we can neglect in eq. 10 
all the terms in the denominator containing к and к , and write: 
с α 
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is a b 
and 
E.I. = log к + log k, (12) 
с α 
This means that within this approximation stereoselectivity is deter­
mined by the two lower binding constants. 
What we are pharmacologically interested in is the change of E.I. 
within a series of compounds. To this end we compare two pairs of isomers. 
Р а І Г І :
 Ь^
 = k
c i k d i = E-R-(,) 
Dis(l) 
pair 2: Уи(2) = к к., = E.R.(2) 
If we take: 
^ ( 2 ) > h.uO) 
it then holds that: 
E. A. Q.
 Е Л
- ( 2 ) -E.I.(l) 
(13) 
l 0 g
 ^(2) - l o e "EUU) 
l o g k
c 2 k d 2 ' l o g k c l k d l 
l o g
 ^ ( 2 ) - l 0 8 K E U C ) 
o r r e p l a c i n g l o g к к , by l o g 1С, - l o g к к, 
c d Eu 0 a b 
* » л ,
 l 0 g k
a 2 k b 2 - l o e k a l k b l 
E.A.Q. = 1 - — (14) 
l 0 g KEu(2) - l 0 g KEu(l) 
Two broad divisions in relation to the E.A.Q. values can be distinguished. 133 
Division I 
If it is assumed that 
k
a. 4l ' ka2 4 2 
and also that 
k
cl kdl < kc2 kd2 
then 
l o e k
a2 kb2 " l 0 8 kal kbl < 1 θ 8 KEu(2) " l 0 8 KEu(l) 
According to eq. 14 it follows that: 
0 < E.A.Q. < 1 
Physically this means that, within a series of pairs of isomers, changes 
in the molecular structure are such, that with the increase of 1С. , 
both the product of the two lower and the two higher affinity constants 
increase. In this case E.I. is an increasing function of log K„ with 
0 < E.A.Q. < 1 such as shown in Fig. 2a. Within this division the 
following limiting situations can be considered: 
Situation 1 
k
al kbl = ka2 Kl 
i.e. the product к к, does not change within the series of isomers 
a b 
considered. Then according to eq. 14: 
E.A.Q. = 1 
Physically this means that within a series of sets of isomers changes 
in the molecular structure are limited to those parts of the molecule 
which only contribute to к and k,, but not to the product of к and 
1
 e d a 
k,. In this case E.I. is an increasing linear function of log Kp with 
an E.A.Q. of 1, such as shown in Fig. 2b. Examples of this case are 
found in Figs. 7 and 8 of part 1. 
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log· 
У] Г -Τ' 
Eu • W à.-^ 
f: •<D194 " > 7 ^ » — * -
/У 
A/ ¿/ 
log К Eu 
E I 
EAQ<1 /\ | EAQ.1
 /^J EAQ.O ,'Ί [EAQ<0 / 1 
L ^ · ' 
I^KEu 
Fig. 2. Some typical eudismia relations. Possible correlations between 
the affinities of a homologous series of enantiomers can be 
sought in two ways: 
i (above): Both the affinity of the eutomer ( • ) and that of 
the distomer ( * ) are plotted against that of the eutomer; 
the line joining the squares obviously has a slope of 1, but 
the drop in affinity for the distomer is apparent. 
ii (below): Here the same data have been plotted in a more com­
pact form; i.e. E.I. (= log KE - log K* . ) vs log К„ (·). 
The slopes of the lines (E.A.Q) correspond to the four limi­
ting cases of eudismia relations considered. 
Situation 2 
cl dl kc2 kd2 
i.e. the product к к, does not change within the series of isomers 
с α 
considered. Then according to eq. 12: 
E.I.(2) - E.I.(l) 0 and E.A.Q. 0 
Physically this means that within a series of sets of isomers changes 
in the molecular structure are limited to those parts of the molecule 
which only contribute to к and k, but not to the product of к and k,. 
a b c d 
In this case E.I. is constant and E.A.Q. = 0 as shown in Fig. 2c. 
Examples of this situation arc found in Fig. 2 and E.A.C. H 3 and 26 of 
table 1 of part I . 
Within the latter situation only two cases can be distinguished. 
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a) E.I. is zero, i.e. there is no stereoselectivity. This can occur if 
only two groups are effectively interacting, the third and fourth groups 
either will not interact at all (the receptor has only two sites) or 
their binding contributions to existent third and fourth sites are ne­
gligible. 
b) E.I. is constant but different from zero, i.e. the series displays 
constant stereoselectivity. This can occur if only a and/or Ъ are being 
varied and groups e and d remain unchanged throughout the series, i.e. 
E.I. = log к + log к, = constant. 
в
 с d 
Division II 
If it is assumed that 
k
al kbl < ka2 kb2 
and also that 
k
cl kdl > kc2 kd2 
then 
1 0 8 k
a2 kb2 - l o e kal Чі > l o g ^ ( 2 ) " 1 о 8 KEu(l) 
According to eq. 20 it follows that: 
E.A.Q. < 0 
Physically this means that within a series of pairs of isomers, changes 
in the molecular structure are such that pirt of the increase in K„ as 
Eu 
caused by the groups with the largest contribution to the overall sta­
bility of the complex is lost by a decrease in the contributions of the 
other groups. In that case E.I. ts a decreastnq functvon of loa К^ 
Wbth E.A.Q. < 0, such as shown in Fig. 2d This case is the special one 
which was excluded fron the general consideration in relation to eq. 10. 
Examples of tms case are found in Fig 8 and F А С H 23 of table 1 of 
part 1 . 
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DISCUSSION 
GENERAL OCCURRENCE OF EUDISMIC-AFFINITY CORRELATIONS 
The model for drug-receptor interaction, as described before, shows the 
general trends for stereoselectivity discussed in part 1 (II). 
Remarkably, this even holds true if for the group affinity constants 
particular assumptions are made such as к >> к , while then also the 
limiting situations E.A.Q. = I and E.A.Q. = 0 evolve. This is partly in­
herent in the way stereoselectivity is treated here, i.e. plots of the 
interrelated variables E.I. and log 1С, limit the number of possible 
slopes. Nevertheless it implies, as shown in equation 12, that stereo­
selectivity is determined by those group affinity constants which make 
the lowest contribution to the overall affinity constant. Since the 
condition к >> к will often be fulfilled, the general occurrence of 
а с » ь 
eudismic affinity correlations can be explained on this basis. In part 
1 a few cases were encountered with an E.A.Q. greater than unity. The 
model used does not predict the existence of such a relation. It is 
likely that in such cases these E.A.Q. values are determined by steps 
subsequent to binding. In fact, the above mentioned cases all involve 
the correlation of enzymatic turnover data. 
GROUP AFFINITY CONSTANTS 
The usefulness of the model presented would increase greatly if the 
group affinity constants utilized could be interpreted as intrinsic 
group affinity constants like those used in the correlation of reaction 
rates (12, 13), or biological activity (14, 15), with physico-chemical 
parameters. These would be constant throughout different drug series 
and biological systems, enabling the prediction of stereoselectivity. 
In fact we (Lien et al., 16) have shown that the stereoselectivity of a 
series of phenoxypropionic acids acting as plant growth regulators can 
be explained if the physicochemical constants of the two chiral substi-
tuents are treated as independent variables. 
In the determination of the group affinity constants, defined 
above, a number of complications will, however, be encountered. First 
of all it has to be assumed that the observed biological activity de­
pends linearly on the affinity. In neglecting intrinsic activity and k. 
for enzymatic reactions for the moment, the next difficulty encountered 
concerns the process of binding of a molecule to its binding site or 
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receptor, which may be quite complicated. From a number of kinetic 
studies of substrate binding to proteins (17-19), evidence is accumu­
lating that often association rate constants are not diffusion-limited. 
This has been interpreted to mean that in this type of binding process 
a pre-equilibrium condition is established before all interacting groups 
become attached. Other work (20, 21) has shown that in multistep complex 
formation, involving identical groups, nucleation and propagation steps 
can be distinghuised. In general, once nucleation has occurred, propa­
gation is rather easy and similar for all subsequent interactions. An­
other point which has to be taken into account is that the sequence of 
formation of R=§F, indicated in eq. 3, is not the only possible one; 
other sequences such as a -> с -• b -»• d might be considered as well. Al­
though the overall affinity constants K^ and 1С. are, of course, in­
dependent of the sequence followed, one should question whether the in­
dividual group affinity constants are equal for each sequence and whether, 
for example, k, in eq. 8 has the same value as k, in eq. 9. 
If however, the sequence of complex formation can be described by a 
nucleation step and a propagation step, and if the nucleation step is 
confined to the first interacting group (a or b) then at least the value 
of the product of k k, in the numerator and denominator of eq. II will 
be the same and independent of the reaction sequence. This makes the as­
sumption that eq. 12 is independent of the sequence of binding steps 
quite reasonable. Moreover, as eq. 12 states that stereoselectivity is 
determined only by k and k , and if, as is assumed above, the correspon­
ding groups are not involved in nucleation, it is quite possible that 
they might turn out to be adequate substituent constants, useful in pre­
dicting stereoselectivity. 
The model presented is simple and adequate to explain the relation 
of stereoselectivity and affinity in general. It is not possible yet, 
however, to correlate the group affinity constants of the model to the 
particular groups in the stereoisomers. 
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SUMMARY AND CONCLUSIONS 
In part I of these two papers (11) experimental evidence is given for 
particular relationships between the ratio of the activities (potencies) 
of pairs of optical isomers in relation to the activity of the more po-
tent isomer of the pair. This ratio in general increases with the acti-
vity of the more potent isomer. This relationship occurs among such a 
wide variety of bioactive systems (see part 1) that a general principle 
underlying the phenomenon becomes probable. 
In this part, on the basis of a simplified drug-receptor inter-
action model and with emphasis on the contributions to the overall affi-
nity by the various (four) ligands at the chiral center, this general 
principle has been rationalized. The relations observed experimentally 
are explained in terms of the group affinity constants involved. The 
model predicts the prevalence of a positive correlation between the 
ratios of activities of the pairs of isomers and the activity of the 
more potent isomer. 
Further general trends that follow from the analysis given are: 
1. The slope of the curve representing the relationship will not exceed 
unity when only affinities are correlated. 
2. A negative value for the slope of the curve representing the rela-
tionship is only to be expected under particular conditions, namely 
if, with the increase in the affintiy of the more active isomer, 
there is a concomitant and larger increase in the affinity of the 
less active isomer such that the latter still remains less active 
than the first. This implies that such a relationship will only oc-
cur over a small span of activities. 
The analysis presented also indicates that it should be possible 
to obtain "substituent" constants useful in predicting stereoselectivi-
ty. The experimental data required for such a procedure are not suffi-
ciently available yet. 
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SUmARY 
When designing new drugs the aim should be to obtain a drug with opti­
mal selectivity rather than high activity. In this way unwanted side 
effects will be avoided. In general a high selectivity of a drug will 
be based on a high degree of complementarity of the chemical properties 
of the drug and the site of interaction in the body - the receptor -
where the desired effect is induced. Therefore, this complementarity 
must be as complete as possible: the interaction must have a high de­
gree of specificity. The objective of the study described in this 
thesis is to contribute to the insight in the factors determining the 
specificity of the interaction between the drug and its receptor. 
Section I deals with the question in how far the hydrophobic inter­
action between a part of the pharmacon molecule and a part of the recep­
tor can play a role in the specificity. In the literature a correlation 
between activity and lipophilicity inside series of bioactive agents is 
reported quite often. The partition coefficient is then commonly used 
as a measure for the lipophilicity. However, since a great diversity of 
drugs is concerned the significance of the lipophilicity in the selec­
tivity of the interaction seems to be small. A lipophilicity parameter 
such as the partition coefficient or π gives only an indication of a 
general property and does not express its spatial aspects. Such a para­
meter therefore is unsuitable for approaching the selectivity in action. 
For those cases in which the receptor is located on a protein it can be 
expected - taking into account the structure of proteins - that the 
hydrophobic binding areas are small. Thus it seems probable that hydro­
phobic binding can play a role in the selectivity. This problem has 
been investigated experimentally by determining the affinity constants 
for the binding to albumin of a series of successive fatty acids (pro­
pionic acid to nonanic acid) at two temperatures. The values of the 
standard free energy change, ΔΟ , for the binding to the specific 
binding site, as derived from the affinity constants, do not increase 
linearly with the increase in chain length. Between valeric acid and 
heptanoic acid the values show a plateau. The occurrence of the plateau 
can be interpreted as being the consequence of a restricted size of the 
hydrophobic binding area of albumin for the fatty acids. A similar dis­
continuity in the dependence of AG on the chain length has been ob­
served for other protein systems. Therefore it is probable that a re-
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stricted size of hydrophobic binding areas is a general feature of pro­
teins. This knowledge could be employed to increase the selectivity in 
action of bioactive agents. 
Section II reports the study of the binding of acetrizoate to al­
bumin by means of nuclear magnetic resonance (nmr). Acetrizoate shows a 
pronounced selectivity with regard to the various binding sites of al­
bumin. The ratio of the affinity constants of the first and remaining 
binding sites is about 1000. The nmr signals show a linewidth increase 
and a shift as a result of the binding. These changes in the spectrum 
are determined by the exchange rate of the pharraacon molecule between 
bound and not-bound state, by the mobility of the various groups of the 
molecule and the active site on the receptor, and by their mutual dis­
tances. From the linewidth measurements, values could be determined for 
the association and dissociation rate constants of the two types of 
complexes. It appears that an increase of the affinity constant is much 
more coupled with an increase of the association rate constant, rather 
than with a decrease of the dissociation rate constant. The specific 
interaction shows a much higher association rate constant (2.5 χ 10 
sec M ) than the non-specific one (2 χ 10 sec M ). Obviously, 
neither of the two rate constants are diffusion limited. The influence 
of the dissociation rate constant of the specific complex on the effi­
ciency of renal excretion has been checked in model calculations. 
The increase in linewidth provides information about the mobility 
of the groups of the molecule in the bound state. In the case of the 
non-specific complex, this information has been used to estimate the 
mobilities of the methyl group and the phenyl proton. Both groups in 
this complex show residual mobility with regard to the albumin molecule. 
Section III deals with the difference in biological activity of 
stereoisomers. The fact that these differences occur emphasizes the role 
of the spatial aspects in the selectivity of interaction. A difference 
in activity of enantiomers is really only explicable if at the inter­
action site of the more active isomer at least three, spatial separated, 
interaction points are involved. Λ literature survey of relevant expe­
rimental data shows that often a remarkable relationship exists between 
the ratio of the activities of the enantiomers on one side and the ac­
tivity of the more active isomer on the other. This leads to the expec­
tation of a general basic principle underlying this phenomenon. 
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The observed correlations can be rationalized on the basis of a simple 
theoretical model for diastereomeric interactions. Emphasis is laid on 
the individual contributions of the groups, attached to the chiral car-
bon atom, to the overall affinity of the drug molecule to its receptor. 
S/WENVATTING 
Bij het ontwerpen van nieuwe geneesmiddelen is het niet primair van be-
lang om hoog werkzame verbindingen te verkrijgen maar veel meer om de 
selectiviteit van het geneesmiddel zo optimaal mogelijk te maken. Men 
vermijdt hierdoor het optreden van ongewenste bijwerkingen. Aangezien 
de selectiviteit van het geneesmiddel in de regel zal berusten op een 
hoge mate van complementariteit van de chemische eigenschappen van het 
geneesmiddel met die van de plaats van interactie in het lichaam, de 
receptor, al waar het gewenste effect wordt geïnduceerd, zal deze com-
plementariteit zo goed mogelijk moeten zijn; de interactie zal een hoge 
mate van specificiteit moeten bezitten. Het is het doel van de onder-
zoekingen, beschreven in dit proefschrift, om het inzicht te verruimen 
in de factoren die de specificiteit van de interactie van het genees-
middel met zijn receptor bepalen. 
In sectie I wordt nagegaan in hoeverre de hydrofobe interactie van 
een deel van het farmaconmolecuul met een deel van de receptor een rol 
kan spelen in de specificiteit van de interactie van het farmaconmole-
cuul met zijn receptor. In de literatuur wordt veelvuldig melding ge-
maakt van een correlatie tussen werkzaamheid en lipofiliteit binnen 
reeksen van bioactieve stoffen. Hierbij wordt de verdelingscoëfficiënt 
in de regel als maat voor de lipofiliteit gehanteerd. Daar het hier een 
grote diversiteit van verbindingen betreft lijkt de betekenis van de 
lipofiliteit in de selectiviteit van de interactie gering. Een lipofili-
teitsparameter, zoals verdelingscoëfficiënt of π, geeft echter slechts 
een algemene hoedanigheid weer en geeft geen uitdrukking aan de ruimte­
lijke aspecten ervan. Een dergelijke parameter is dan ook niet geschikt 
om de selectiviteit in werking te benaderen. Voor die gevallen dat de 
receptor gelokaliseerd is op een eiwit kan op grond van de bouw van het 
eiwit verwacht worden dat de hydrofobe bindingsgebieden beperkt in om­
vang zijn. Hiervan uitgaande, is het waarschijnlijk dat hydrofobe bin­
ding wel een rol kan spelen bij de selectiviteit in werking. Experimen­
teel is dit vraagstuk aangepakt door het bepalen van affiniteitsconstan­
ten voor de binding aan albumine van een reeks opeenvolgende vetzuren 
(propionzuur tot nonaanzuur) bij twee temperaturen. De hiervan afgeleide 
standaardvrije energieverandering, AG , voor de binding aan de speci­
fieke bindingsplaats neemt, met het langer worden van de vetzuurstaart, 
niet monotoon toe. Bij valeriaanzuur wordt een plateau in Δ0 bereikt 
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en pas bij heptaanzuur neemt AG verder toe. Het optreden van het pla-
teau in AG kan worden gezien als een afspiegeling van de beperkte om-
vang van het hydrofobe bindingsgebied van albumine voor vetzuren. Aan-
gezien voor andere eiwitsystemen soortgelijke discontinuïteiten in de 
afhankelijkheid van ΔΟ van de ketenlengte zijn vastgesteld is het 
waarschijnlijk dat de beperktheid in de grootte van de hydrofobe bin-
dingsgebieden een algemeen kenmerk voor eiwitten is. Deze kennis zou 
benut kunnen worden om de selectiviteit in de werking van geneesmiddelen 
te verhogen. 
In sectie II is de binding van acetrizoaat aan albumine met behulp 
van kernmagnetische resonantie (nmr) onderzocht. Acetrizoaat vertoont 
een duidelijke selectiviteit t.a.v. verschillende bindingsplaatsen op 
het albumine. De affiniteitsconstanten van de eerste bindingsplaats en 
die van de overige bindingsplaatsen verhouden zich ongeveer als 1000 : 1. 
De nmr signalen verbreden en verschuiven als gevolg van de binding van 
acetrizoaat aan albumine. Deze veranderingen in het spectrum worden be­
paald door de overgangsnelheid van het farmacon van de gebonden naar de 
niet gebonden toestand en omgekeerd, de beweeglijkheid van de afzonder­
lijke groepen in het farmaconmolecuul en de actieve plaats op de recep­
tor, en de onderlinge afstand van deze groepen. Uit de lijnbreedte-
metingen konden waarden voor de associatie- en dissociatiesnelheids-
constanten voor de twee soorten complexen worden bepaald. Hieruit blijkt 
dat een toename in de affiniteitsconstanten niet gepaard gaat met een 
afname van de dissociatiesnelheidsconstante maar met een toename in de 
associatiesneldheidsconstante. De specifieke interactie heeft een veel 
hogere (2,5.10 sec M ) associatiesnelheidsconstante dan de niet 
3 -1 -1 
specifieke (2.10 sec M ) interactie. Beide associatiesnelheden 
worden duidelijk niet bepaald door de diffusiesnelheid. In modelbere­
keningen werd de invloed van de dissociatiesnelheid van het specifieke 
acetrizoaat-albumine complex op de effectiviteit van de renale klaring 
nagegaan. De informatie die de lijnverbreding biedt omtrent de beweeg-
lijkheden der groepen kon in geval van de niet specifieke interactie 
worden aangewend om de beweeglijkheden van de methylgroep en het aro-
maatproton te benaderen. Beide groepen bleken in dit complex nog een 
residuele beweeglijkheid ten opzichte van het albumine te bezitten. 
In sectie III zijn de biologische activiteiten van stereo-isomeren 
onderling vergeleken. Het optreden van verschillen in werkzaamheid 
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van enantiomeren accentueert de betekenis van de ruimtelijke structuur 
voor de selectiviteit in de interactie. Een verschil in werkzaamheid 
van enantiomeren is immers slechts verklaarbaar indien bij de interactie 
tussen de meest werkzame isomeer van het farmacon en de receptor minstens 
drie ruimtelijk gescheiden interactiepunten betrokken zijn, Aan de hand 
van een literatuuroverzicht van relevante experimentele gegevens wordt 
aangetoond dat vaak een opvallend verband bestaat tussen de verhouding 
der activiteiten van de enantiomeren en de activiteit van meest werkzame 
isomeer. Deze relatie blijkt zo algemeen dat ze pleit voor een algemeen 
principe als grondslag ervoor. Aan de hand van een eenvoudig theoretisch 
model voor diastereomere interacties kunnen de waargenomen correlaties 
verklaard worden. Er wordt hierbij de nadruk gelegd op de afzonderlijke 
bijdragen van de, aan het asymmetrische koolstofatoom bevestigde, groepen 
aan de totale affiniteit van het farmaconmolecuul voor zijn receptor. 
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STELLINGEN 
I 
Kennis omtrent de afzonderlijke bijdragen van groepen in het farmacon-
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inzicht in het mechanisme van selectiviteit in werking wezenlijk ver-
groten. Het verband tussen de temperatuur en de correlatietijden van 
de afzonderlijke groepen, zoals dat uit de nmr-lijnbreedten is af te 
leiden, zou een indicatie voor de grootte van deze bijdragen kunnen 
zijn. 
A. Lanir en G. Navon, Biochem. K>.» '024 (1971). 
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III 
De onderlinge posities en grootten van lipofiele bindingsgebieden, 
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onderzocht. Hierbij dient de positie van een polaire groep in de ali-
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VII 
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Vili 
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